

Respuesta a Requerimientos

1	Datos del Solicitante				
Nombre:	MARGARITA CASTELLANOS ABONDANO	Dirección Electrónica:	sic@castellanosyco.co		
Dirección:	CALLE 94A 7A 09	Domicilio/País de constitución:	COLOMBIA - BOGOTA D.C. - BOGOTA D.C.		
Identificación:					
☒ CEDULA DE CIUDADANIA ☐ EMPRESA EXTRANJERA ☐ PASAPORTE		☐ CEDULA DE EXTRANJERIA ☐ NIT			
Número:	39779654-				
2	Dato de la Creación				
Identificación de la Creación	No. de Certificado	Vigencia	No. de Expediente	Tipo Trámite	
ENVASE DE MEDICAMENTO, METODO PARA ENSAMBLAR EL ENVASE Y METODO PARA DISPENSAR EL MEDICAMENTO DEL ENVASE	000000		16019883	PCT-PATENTE DE INVENCION CAPITULOS I Y II	

3	Texto de la Comunicación	Se adjunta memorial de respuesta a Oficio de Forma No. 1677, junto con un nuevo pliego reivindicatorio conformado por veinte (20) reivindicaciones, formulario de solicitud PPH y los documentos relativos al PPH.
4	Anexos	
☒ Anexos		

Señor
Director de la Dirección de Nuevas Creaciones
Superintendencia de Industria y Comercio
Ministerio de Comercio, Industria y Turismo
E. S. D.

Re.: Expediente No. **16 019883**
Solicitud de Patente PCT entrada en Fase Nacional, para:
**“ENVASE DE MEDICAMENTO, MÉTODO PARA ENSAMBLAR EL ENVASE Y
MÉTODO PARA DISPENSAR EL MEDICAMENTO DEL ENVASE”**
Solicitante: **ABBVIE INC.**

RESPUESTA A EXAMEN DE FORMA

Yo, **MARGARITA CASTELLANOS ABONDANO**, mayor de edad, identificada y domiciliada como aparece al pie de mi firma, obrando en mi calidad de apoderada de la sociedad solicitante del asunto citado en la referencia, en atención a su oficio No. **1677** notificado el **23 de febrero de 2016** atentamente me permito dar respuesta al mismo de la siguiente manera:

1. Solicitud PPH

Junto con el presente memorial se adjunta el formulario de solicitud de PPH para la solicitud de la referencia, junto con los siguientes documentos:

- ✓ Copia del resultado del examen de la USPTO (Notificación de Aceptación) que indica las reivindicaciones permitidas o patentables y su respectiva traducción al español.
- ✓ Copia de la citación del arte previo citado por el examinador de Estados Unidos, con su respectiva traducción al español.
- ✓ Copia de las reivindicaciones como fueron otorgadas por la Oficina de Marcas y Patentes de Estados Unidos, con su respectiva traducción al español.
- ✓ Documento US9241873B2 correspondiente a la publicación de la patente otorgada en Estados Unidos de América.

2. Modificación a las Reivindicaciones

De acuerdo con lo establecido en el Artículo 34 de la Decisión 486 y en vista de las observaciones realizadas por el examinador, se presenta en esta oportunidad un nuevo pliego reivindicatorio conformado por veinte (20) reivindicaciones.

Este nuevo pliego reivindicatorio corresponde al otorgado por la Oficina de Patentes de Estados Unidos. No obstante, se han introducido los números de referencia de las partes correspondientes en las reivindicaciones, de acuerdo a las figuras de la presente solicitud.

Se solicita atentamente tener en cuenta este nuevo pliego reivindicatorio para el análisis de patentabilidad, toda vez que no implica una ampliación de la materia inicialmente solicitada y además permite superar las objeciones comunicadas por el examinador.

3. Conclusión

Teniendo en cuenta los documentos aportados, es posible establecer que las reivindicaciones cumplen con los requerimientos de la Decisión 486.

En consecuencia, se solicita atentamente continuar su trámite y ordenar su publicación.

4. Anexos

- ✓ Nuevo pliego reivindicatorio conformado por veinte (20) reivindicaciones.
- ✓ Formulario de solicitud de PPH.
- ✓ Copia del resultado del examen de la USPTO (Notificación de Aceptación) que indica las reivindicaciones de la solicitud 14/323,701 permitidas o patentables y su respectiva traducción al español.
- ✓ Copia de la citación del arte previo citado por el examinador de Estados Unidos, con su respectiva traducción al español.
- ✓ Copia de las reivindicaciones como otorgadas por la Oficina de Marcas y Patentes de Estados Unidos, con su respectiva traducción al español.
- ✓ Copia de publicación internacional de la solicitud equivalente otorgada en Estados Unidos bajo el número de solicitud 14/323,701

Señor Director,



Margarita Castellanos Abondano

C.C. No. **39.779.654** de Bogotá

T.P.A. No. **70.819** del C.S.J.

Calle 94A No. 7A-09 - Bogotá, D.C.

Teléfono: 7560770

Bogotá, D.C.

MCA/lt

P4299

RESPUESTA EXAMEN DE FORMA

REIVINDICACIONES MODIFICADAS EN RESPUESTA AL EXAMEN DE
FORMA Y PPH

1. Un conjunto de envase de medicamento a prueba de niños (10), CARACTERIZADO PORQUE comprende:

un envase blíster (20) que incluye una pluralidad de compartimientos (40), configurado cada uno de la pluralidad de compartimientos (40) para sostener al menos un medicamento (42);

una plancha (100) que incluye un hueco (112) que tiene una pluralidad de aberturas (116), correspondiendo cada abertura de la plancha a uno de la pluralidad de compartimientos (40) del blíster (20); y

una caja (150) que incluye una primera pared (158) opuesta a una segunda pared (162), una pluralidad de aberturas (170) que se extienden a través de la primera pared (158), alineadas cada una de las aberturas (170) de la primera pared (158) con las correspondientes perforaciones (178) de la segunda pared (162), alineadas cada una de las aberturas (170) de la primera pared (158) con una de las aberturas (116) de la plancha (100) y un correspondiente compartimiento (40) del blíster (20).

2. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE cada uno de la pluralidad de compartimientos (40) está separado de la abertura (170) complementaria de la caja (150).

3. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE la caja (150) incluye una serie de instrucciones para administrar el medicamento (42) asegurado dentro de la pluralidad de compartimientos (40) del blíster (20).

4. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE el blíster (20) además incluye una primera región (60) y una segunda región (60'), incluyendo cada una de las regiones primera y segunda al menos uno de la pluralidad de compartimientos (40).

5. El envase de medicamento a prueba de niños (10) de la reivindicación 4, CARACTERIZADO PORQUE la caja (150) además incluye una primera región (194) y una segunda región (194'), comprendiendo cada una de las regiones primera y segunda al menos una de la pluralidad de aberturas (170).

6. El envase de medicamento a prueba de niños (10) de la reivindicación 5, CARACTERIZADO PORQUE la primera región (60) del blíster (20) está alineada con la primera región (194) de la caja (150), y la segunda región (60') del blíster (20) está alineada con la segunda región (194') de la caja (150).

7. El envase de medicamento a prueba de niños (10) de la reivindicación 5, CARACTERIZADO PORQUE la primera región (194) de la caja (150) incluye un primer conjunto de instrucciones para administrar el medicamento (42) asegurado en el al menos uno de la pluralidad de compartimientos (40) de la primera región (194) y donde la segunda región (194') de la caja (150) incluye un segundo conjunto de instrucciones para administrar el medicamento (42) asegurado en el al menos uno de la pluralidad de compartimientos (40) de la segunda región (194').

8. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE la caja (150) está construida de cartulina con una capa de película resistente al desgarro.

9. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE la plancha (100) además incluye una pluralidad de aberturas (116) que se extienden a través del hueco (112), configurada cada una de la pluralidad de aberturas (116) para ser complementaria y estar en alineación con uno de la pluralidad de compartimientos (40).

10. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE la plancha (100) incluye una altura que es mayor que una altura de uno de los compartimientos (40) del blíster (20).

11. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE la plancha (100) está construida de pulpa de papel y fibra de bambú moldeadas.

12. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE el medicamento (42) asegurado de cada uno de la pluralidad de compartimientos (40) es accesible perforando un sello (54) del blíster (20).

13. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE la caja (150) está ensamblada y fijada mediante construcción de extremo engomado.

14. El envase de medicamento a prueba de niños (10) de la reivindicación 1, CARACTERIZADO PORQUE la caja (150) incluye una tercera pared (182) acoplada de modo abisagrado a la primera pared (158), superponiéndose la tercera

pared (182) a la primera pared (158) para impedir el acceso a la pluralidad de aberturas (170) de la caja (150).

15. Un método para ensamblar un envase de medicamento a prueba de niños (10), CARACTERIZADO PORQUE comprende los pasos de:

alinear un envase blíster (20) que incluye una pluralidad de compartimientos (40) con una plancha (100) que incluye un hueco (112) y una pluralidad de aberturas (116), configurada cada una de la pluralidad de aberturas (116) para ser complementaria de uno de la pluralidad de compartimientos (40);

anexar el blíster (20) a la plancha (100);

insertar el blíster (20) y la plancha (100) en una caja (150), incluyendo la caja (150) una primera pared (158) opuesta a una segunda pared (162), una pluralidad de aberturas (170) que se extienden a través de la primera pared (158) y están alineadas con una pluralidad de perforaciones (178) de la segunda pared (162), alineadas cada una de la pluralidad de aberturas (170) y perforaciones (178) para que sean complementarias de uno de la pluralidad de compartimientos (40); y

cerrar la caja (150) para encerrar el blíster (20) y la plancha (100).

16. El método para ensamblar un envase de medicamento a prueba de niños (10) de la reivindicación 15, CARACTERIZADO PORQUE insertar el blíster (20) y la plancha (100) en la caja (150) incluye mantener una separación entre la pluralidad de compartimientos (40) y la pluralidad de aberturas (170) de la primera pared (158).

17. El método para ensamblar un envase de medicamento a prueba de niños (10) de la reivindicación 15, CARACTERIZADO PORQUE fijar el blíster (20) y la plancha (100) dentro de la caja (150) incluye superponer y fijar una tercera pared (182) sobre la primera pared (158).

18. El método para ensamblar un envase de medicamento a prueba de niños (10) de la reivindicación 15, CARACTERIZADO PORQUE además comprende imprimir en la caja (150) una serie de instrucciones para administrar el medicamento (42) asegurado dentro de la pluralidad de compartimientos (40).

19. El método para ensamblar un envase de medicamento a prueba de niños (10) de la reivindicación 15, CARACTERIZADO PORQUE además comprende:

proveer al blíster (20) de una primera región (60) y una segunda región (60'), incluyendo cada una de las regiones primera y segunda al menos uno de la pluralidad de compartimientos (40);

proveer a la caja (150) de una primera región (194) y una segunda región (194'), incluyendo cada una de las regiones primera y segunda al menos una de la pluralidad de aberturas (170);

alinear la primera región (60) del blíster (20) con la primera región (194) de la caja (150);

alinear la segunda región (60') del blíster (20) con la segunda región (194') de la caja (150);

imprimir en la primera región (194) de la caja (150) una primera instrucción para administrar el medicamento (42) asegurado dentro del al menos uno de la pluralidad de compartimientos (40) de la primera región (194); e

imprimir en la segunda región (194') de la caja (150) una segunda instrucción para administrar el medicamento (42) asegurado dentro del al menos uno de la pluralidad de compartimientos (40) de la segunda región (194').

20. Un método para dispensar a un usuario el medicamento (42)

asegurado dentro de un envase a prueba de niños (10), CARACTERIZADO PORQUE comprende los pasos de:

proveer un envase (10) que incluye una caja (150), una plancha (100) y un envase blíster (20), fijada la plancha (100) a la caja (150), y fijado el blíster (20) a la plancha (100);

aplicar un fuerza al menos a un compartimiento de una pluralidad de compartimientos (40) del blíster (20), alineado cada uno de la pluralidad de compartimientos (40) con una complementaria de una pluralidad de aberturas (170) de una primera pared (158) de la caja (150);

romper un sello (54) del al menos un compartimiento (40) para mover el medicamento (42) contenido en el al menos un compartimiento (40);

expulsar el medicamento (42) a través de una abertura (116) del hueco (112) de la plancha (100), siendo complementaria la abertura (116) del al menos un compartimiento (40); y

expulsar el medicamento (42) a través de una perforación (178) de una segunda pared (162) de la caja (150), siendo complementaria la perforación (178) del al menos un compartimiento (40).

	Espacio reservado para el adhesivo de radicación
---	--

DIRECCIÓN DE NUEVAS CREACIONES
Procedimiento acelerado de exámenes de patente (PPH)

1	NÚMERO DE SOLICITUD ANTE LA SIC	16 019883.
2	OFICINA DE PRIMERA PRESENTACIÓN (OPP)	ESTADOS UNIDOS DE AMERICA
3	NÚMERO(S) DE SOLICITUD O PUBLICACIÓN DE LA(S) SOLICITUD(ES) (OPP):	1.14/323,701 2. 3.
4	☐ REPRESENTANTE LEGAL ☒ APODERADO	
APELLIDOS CASTELLANOS ABONDANO		NOMBRES MARGARITA
		IDENTIFICACIÓN C.C . 39'779.654 T.P . 70819
DIRECCIÓN CALLE 94A No. 7A-09		No. TELÉFONO 7560770
CIUDAD BOGOTÁ		CORREO ELECTRÓNICO sic@castellanosyco.co
PAÍS COLOMBIA		No. RADICACIÓN O PROTOCOLO DE PODER GENERAL
5	CONDICIONES PARA ACCEDER A ESTE PROCESO:	
5.1. DATOS DE PRIORIDAD ☒ SI ☐ NO		
(33) PAÍS DE ORIGEN 1. ESTADOS UNIDOS DE AMERICA 2. ESTADOS UNIDOS DE AMERICA 3. ESTADOS UNIDOS DE AMERICA		CÓDIGO PAÍS US US US
		(31) NÚMERO 61/842,841 61/842,900 29/488,207
		(32) FECHA (AAAA/MM/DD) 2013/07/03 2013/07/03 2014/04/16
5.2. DATOS SOLICITUD INTERNACIONAL PCT ☒ SI ☐ NO		
Solicitud Internacional No. PCT/US2014/045459		Fecha 03/07/2014
Publicación Internacional No. WO2015/003158		Fecha 08/01/2015
El solicitante presenta una copia de la(s) reivindicación(es) patentable(s) u otorgable(s) de la solicitud de la Oficina de Primera Presentación que profirió el examen de patentabilidad, junto con una traducción al castellano. ☒ SI ☐ NO		
REQUISITOS PARA EL RECONOCIMIENTO DE LOS RESULTADOS DE EXÁMENES DE PATENTABILIDAD EFECTUADOS A SOLICITUDES EXTRANJERAS		
Para que la Superintendencia de Industria y Comercio pueda reconocer los resultados de exámenes de patentabilidad producidos por otras Oficinas de Propiedad Industrial se debe cumplir con las siguientes condiciones:		
(a) Al momento de solicitar el examen de patentabilidad, si el solicitante pide que se reconozcan exámenes de patentabilidad de otras oficinas extranjeras, deberá aportar junto con el pago de la tasa correspondiente, los siguientes anexos:		
(i) Copia de las resoluciones, fallos o decisiones que han sido relevantes para la determinación de la patentabilidad de la(s) solicitud(es) en la Oficina que haya proferido el examen de patentabilidad que contienen reivindicaciones patentables u otorgables que son la base de la petición, y si es del caso, su traducción al castellano. ☒ SI ☐ NO		
(ii) Copia de todas las reivindicaciones determinadas como patentables u otorgables en la Oficina que profirió el examen de patentabilidad y, si es del caso, su traducción al castellano. ☒ SI ☐ NO		
(iii) Copia de los antecedentes, información o documentos citados por el examinador de la Oficina de Primera Presentación del examen de patentabilidad, en las resoluciones, fallos o decisiones correspondientes, incluyendo la literatura no patente. Los documentos de patente deberán presentarse siempre y cuando no estén disponibles para la Superintendencia de Industria y Comercio mediante el simple acceso a bases de datos gratuitas. ☒ SI ☐ NO		
(iv) Una tabla de correspondencias de las reivindicaciones que han sido determinadas como patentables u otorgables en la solicitud de la Oficina que haya proferido el examen de patentabilidad. ☒ SI		

7	FIRMA DEL SOLICITANTE, DEL APODERADO O DEL REPRESENTANTE LEGAL <i>Junto a cada firma, indicar el nombre del firmante y su calidad (si tal calidad no es obvia al leer el petitorio)</i>
---	---



Margarita Castellanos (Apoderada)

6	TABLA DE CORRESPONDENCIA DE REIVINDICACIONES	
	US	CO
Reivindicación 1 y 15	Contienen el término “<i>que comprende</i>” en cada una de las reivindicaciones. No contiene los números de referencia de cada una de las partes del envase del medicamento.	Se utiliza la expresión “<i>caracterizado por</i>” en cada una de las reivindicaciones. A fin de darle claridad a las reivindicaciones, se han incluido los números de referencia de cada una de las partes del envase del medicamento de conformidad con las figuras de la presente solicitud.
Reivindicación 2 a 14 y 16 a 20	Contienen el término “<i>donde</i>” en cada una de las reivindicaciones. No contiene los números de referencia de cada una de las partes del envase del medicamento.	Se utiliza la expresión “<i>caracterizado por</i>” en cada una de las reivindicaciones. A fin de darle claridad a las reivindicaciones, se han incluido los números de referencia de cada una de las partes del envase del medicamento de conformidad con las figuras de la presente solicitud.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

17567 7590 09/30/2015
Michael Best & Friedrich LLP (AbbVie)
Two Prudential Plaza
180 North Stetson Avenue, Suite 2000
Chicago, IL 60601

EXAMINER

BUI, LUAN KIM

ART UNIT

PAPER NUMBER

3728

DATE MAILED: 09/30/2015

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

14/323,701

07/03/2014

Guy Upchurch

031777-1823-06/11912USO1

4322

TITLE OF INVENTION: MEDICINE CONTAINER, METHOD OF ASSEMBLING THE CONTAINER, AND METHOD OF DISPENSING THE MEDICINE FROM THE CONTAINER

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	12/30/2015

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

17567 7590 09/30/2015
Michael Best & Friedrich LLP (AbbVie)
Two Prudential Plaza
180 North Stetson Avenue, Suite 2000
Chicago, IL 60601

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/323,701	07/03/2014	Guy Upchurch	031777-1823-06/11912USO1	4322

TITLE OF INVENTION: MEDICINE CONTAINER, METHOD OF ASSEMBLING THE CONTAINER, AND METHOD OF DISPENSING THE MEDICINE FROM THE CONTAINER

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	12/30/2015

EXAMINER	ART UNIT	CLASS-SUBCLASS
BUI, LUAN KIM	3728	206-531000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.	2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____ (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____ 3 _____
---	---

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee
☐ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☐ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
☐ Applicant asserting small entity status. See 37 CFR 1.27
☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____
Typed or printed name _____ Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/323,701	07/03/2014	Guy Upchurch	031777-1823-06/11912USO1	4322

17567 7590 09/30/2015
Michael Best & Friedrich LLP (AbbVie)
Two Prudential Plaza
180 North Stetson Avenue, Suite 2000
Chicago, IL 60601

EXAMINER

BUI, LUAN KIM

ART UNIT	PAPER NUMBER
----------	--------------

3728

DATE MAILED: 09/30/2015

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

<i>Notice Requiring Inventor's Oath or Declaration</i>	Application No. 14/323,701	Applicant(s) Guy Upchurch	
	Examiner BUI, LUAN KIM	Art Unit 3728	

This notice is an attachment to the Notice of Allowability (PTOL-37), or the Notice of Allowability For A Design Application (PTOL-37D).

An inventor's oath or declaration in compliance with 37 CFR 1.63 or 1.64 executed by or with respect to each inventor has not yet been submitted.

An oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each inventor (for any inventor for which a compliant oath, declaration, or substitute statement has not yet been submitted) **MUST** be filed no later than the date on which the issue fee is paid. See 35 U.S.C. 115(f). Failure to timely comply will result in ABANDONMENT of this application.

A properly executed inventor's oath to declaration has not been received for the following inventor(s):

If applicant previously filed one or more oaths, declarations, or substitute statements, applicant may have received an informational notice regarding deficiencies therein.

The following deficiencies are noted:

INFORMAL ACTION PROBLEMS

- A properly executed inventor's oath or declaration has not been received for the following inventor(s): **Guy Upchurch** and **John G. Finch**.

Applicant may submit the inventor's oath or declaration at any time before the Notice of Allowance and Fee(s) Due, PTOL-85, is mailed.

Questions relating to this Notice should be directed to the Application Assistance Unit at 571-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 14/323,701	Applicant(s) UPCHURCH ET AL.	
	Examiner Luan K. Bui	Art Unit 3728	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the application filed on 7/3/2014.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 1-20. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some *c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| 1. ☒ Notice of References Cited (PTO-892) | 5. ☐ Examiner's Amendment/Comment |
| 2. ☒ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date <u>See Continuation Sheet</u> | 6. ☐ Examiner's Statement of Reasons for Allowance |
| 3. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 7. ☐ Other _____. |
| 4. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____. | |

/Luan K. Bui/
Primary Examiner, Art Unit 3728

Continuation of Attachment(s) 2. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date: 10/9/14; 4/27/15; 6/2/15.

Notice of References Cited	Application/Control No. 14/323,701	Applicant(s)/Patent Under Reexamination UPCHURCH ET AL.	
	Examiner Luan K. Bui	Art Unit 3728	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-3,921,804 A	11-1975	Tester; William W.	B65D83/0463	206/531
*	B	US-5,109,984 A	05-1992	Romick; Jerome M.	B65D83/0463	206/531
*	C	US-5,489,025 A	02-1996	Romick; Jerome M.	A61J7/0076	206/531
*	D	US-6,082,544 A	07-2000	Romick; J. M.	B65D83/0463	206/531
*	E	US-2003/0042167 A1	03-2003	Balz, Eric R.	B65D83/0463	206/531
*	F	US-2006/0163110 A1	07-2006	Adler; Deborah B.	B65D1/0223	206/534
*	G	US-2009/0301924 A1	12-2009	Rondeau; Gilles	B65D83/0463	206/531
*	H	US-7,748,535 B2	07-2010	Grosskopf; Glenn A.	A61J1/035	206/531
*	I	US-2012/0261275 A1	10-2012	Intini; Derek	A61J1/035	206/532
*	J	US-8,757,381 B2	06-2014	Bouthiette; Michel	B65D1/34	206/528
	K	US-				
	L	US-				
	M	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		14323701
	Filing Date		2014-07-03
	First Named Inventor	Guy Upchurch	
	Art Unit	3728	
	Examiner Name	Not Yet Known	
	Attorney Docket Number	031777-1823-06	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	RE29705		1978-07-18	Compere	
	2	3288281		1966-11-29	Sparks	
	3	3305077		1967-02-21	Greif et al.	
	4	4120400		1978-10-17	Kotyuk	
	5	4192422		1980-03-11	Kotyuk	
	6	4340141		1982-07-20	Fischer	
	7	5050739		1991-09-24	Hannan et al.	
	8	5740717		1998-04-21	Sowden et al.	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

	9	6138830		2000-10-31	Muggli	
	10	6443307		2002-09-03	Burridge	
	11	6516949		2003-02-11	Fuller et al.	
	12	6679382		2004-01-20	Kancsar et al.	
	13	6793077		2004-09-21	Kancsar et al.	
	14	6896139		2005-05-24	Kancsar et al.	
	15	6997320		2006-02-14	Kancsar et al.	
	16	7063211		2006-06-20	Williams-Hartman	
	17	7126879		2006-10-24	Snyder	
	18	7188728		2007-03-13	Williams-Hartman	
	19	7448496		2008-11-11	Williams-Hartman	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

	20	7641050		2010-01-05	Klatt et al.	
	21	7665610		2010-02-23	Williams-Hartman	
	22	7696236		2010-04-13	Bradford	
	23	7748535		2010-07-06	Grosskopf	
	24	7767700		2010-08-03	Bradford	
	25	7784250		2010-08-31	Grosskopf	
	26	7900772		2011-03-08	Sack et al.	
	27	7905355		2011-03-15	Williams-Hartman	
	28	7926660		2011-04-19	Jones et al.	
	29	7967144		2011-06-28	Sack et al.	
	30	7997411		2011-08-16	Williams-Hartman	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

	31	8132671		2012-03-13	Hession	
	32	8205752		2012-06-26	Sack et al.	
	33	8342330		2013-01-01	Weston et al.	
	34	8342331		2013-01-01	Ziembra et al.	
	35	8403212		2013-03-26	van Esch	
	36	8413813		2013-04-09	Grosskopf	
	37	8420674		2013-04-16	Bradford	
	38	8479921		2013-07-09	Ingraham	
	39	8544650		2013-10-01	Williams-Hartman	
	40	8550248		2013-10-08	Busen	
	41	8556077		2013-10-15	Hanley	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

	42	8561798		2013-10-22	Hession	
	43	8567606		2013-10-29	Bellamah et al.	
	44	8573403		2013-11-05	Stevens et al.	
	45	8579106		2013-11-12	Naik et al.	
	46	8584857		2013-11-19	Ozawa et al.	
	47	8602218		2013-12-10	Grosskopf	
	48	8607982		2013-12-17	Jones	
	49	8607983		2013-12-17	Niven et al.	
	50	8627957		2014-01-14	Ziembra et al.	
	51	8640917		2014-02-04	Kracke	
	52	8672134		2014-03-18	Sprada et al.	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

	53	8740003		2014-06-03	Elliott	
	54	8746454		2014-06-10	Doucet et al.	
	55	8752704		2014-06-17	Leon Alonso et al.	
	56	8757381		2014-06-24	Bouthiette	
	57	D263559		1982-03-30	Poore	
	58	D293887		1988-01-26	Webster	
	59	D320930		1991-10-22	Richards	
	60	D322400		1991-12-17	Sorensen	
	61	D322934		1992-01-07	Kalvelage	
	62	D350478		1994-09-13	Fuller et al.	
	63	D351995		1994-11-01	Kalvelage	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

	64	D370414		1996-06-04	Lambelet, Jr.	
	65	D370625		1996-06-11	Kelsey et al.	
	66	D372867		1996-08-20	Lambelet, Jr.	
	67	D382474		1997-08-19	Malmborg	
	68	D404641		1999-01-26	Kelsey et al.	
	69	D411445		1999-06-22	Anderson	
	70	D414106		1999-09-21	Anderson	
	71	D457246		2002-05-14	Mazel et al.	
	72	D480958		2003-10-21	Mazel et al.	
	73	D518737		2006-04-11	Zalzal	
	74	D546198		2007-07-10	Currie et al.	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

	75	D558603		2008-01-01	Priebe et al.	
	76	D622158		2010-08-24	Proulx	
	77	D637391		2011-05-10	Stevens et al.	
	78	D650295		2011-12-13	Schmitz et al.	
	79	D658991		2012-05-08	Schmitz et al.	
	80	D659019		2012-05-08	Specker et al.	
	81	D659550		2012-05-15	Mazor	
	82	D670178		2012-11-06	Carson	
	83	D684482		2013-06-18	Stevens	
	84	D685272		2013-07-02	Stevens	
	85	D688570		2013-08-27	Logue	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	14323701
Filing Date	2014-07-03
First Named Inventor	Guy Upchurch
Art Unit	3728
Examiner Name	Not Yet Known
Attorney Docket Number	031777-1823-06

	86	D688571		2013-08-27	Logue	
	87	D689373		2013-09-10	Logue	
	88	D689374		2013-09-10	Logue	
	89	D689778		2013-09-17	Logue	
	90	D691465		2013-10-15	O'Brien et al.	
	91	D711219		2014-08-19	Palsson	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030034271		2003-02-20	Burridge	
	2	20030164380		2003-09-04	Taneja et al.	
	3	20070185615		2007-08-09	Bossi et al.	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

4	20090038982		2009-02-12	Doucet et al.	
5	20090242451		2009-10-01	Kessler	
6	20110215022		2011-09-08	Sack et al.	
7	20120248005		2012-10-04	Bergey	
8	20130008825		2013-01-10	McArthur et al.	
9	20130193029		2013-08-01	Weston et al.	
10	20130220870		2013-08-29	Grosskopf	
11	20130220871		2013-08-29	Bradford	
12	20130233756		2013-09-12	Weston et al.	
13	20130256183		2013-10-03	Ingraham	
14	20130281960		2013-10-24	Hanley	

Receipt date: 10/09/2014

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit		3728
Examiner Name	Not Yet Known	
Attorney Docket Number		031777-1823-06

	15	20130306511		2013-11-21	Branyon et al.	
	16	20140001194		2014-01-02	Pipes et al.	
	17	20140027340		2014-01-30	Hession	
	18	20140027341		2014-01-30	Ludwig et al.	
	19	20140083900		2014-03-27	Ziamba et al.	
	20	20140171436		2014-06-19	Kamen et al.	
	21	20140183095		2014-07-03	Choubey et al.	
	22	20140209498		2014-07-31	Stevens	
	23	20140214438		2014-07-31	Ahmadi	
	24	20140216968		2014-08-07	Wagner et al.	
	25	20140216977		2014-08-07	Bowers et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Receipt date: 10/09/2014		Application Number		14323701 - GAU: 3728 14323701
			Filing Date		2014-07-03
			First Named Inventor	Guy Upchurch	
			Art Unit	3728	
			Examiner Name	Not Yet Known	
			Attorney Docket Number	031777-1823-06	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add								
FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1211191	EP		2002-05-06	Magnafarma B.V.		☐
	2	2005120984	WO		2005-12-22	Pillot et al.		☐
	3	2010015638	WO		2010-02-11	N.V. Organon		☐
	4	2014057967	WO		2014-04-17	Astellas Pharma Inc		☐
	5	2014085625	WO		2014-06-05	Meadwestvaco Corp		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add			
NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Japanese Office action for Design Application No. 2014-7622 dated April 22, 2014. (1 page)	☐
	2	Japanese Office action for Design Application No. 2014-7623 dated April 22, 2014. (1 page)	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add
--

Receipt date: 10/09/2014

Application Number		14323701 - GAU: 3728 14323701
Filing Date		2014-07-03
First Named Inventor	Guy Upchurch	
Art Unit	3728	
Examiner Name	Not Yet Known	
Attorney Docket Number	031777-1823-06	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

EXAMINER SIGNATURE

Examiner Signature	/Luan K. Bui/ (09/23/2015)	Date Considered	
--------------------	----------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Receipt date: 10/09/2014

14323701 - GAU: 3728

Application Number

14323701

Filing Date

2014-07-03

First Named Inventor

Guy Upchurch

Art Unit

3728

Examiner Name

Not Yet Known

Attorney Docket Number

031777-1823-06

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/julie a. haut/	Date (YYYY-MM-DD)	2014-10-09
Name/Print	Julie A. Haut	Registration Number	51,789

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		14323701
	Filing Date		07-03-2014
	First Named Inventor	UPCHURCH; Guy	
	Art Unit	3728	
	Examiner Name	Luan Kim Bui	
	Attorney Docket Number	11912USO1	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	D254219		1980-02-19	PAPCIAK; W.G.	
	2	D261198		1981-10-31	ALTADONNA; J.	
	3	D268130		1983-03-01	EASTON; H.J.	
	4	D276116		1984-10-30	BASIL M.E. et al.	
	5	D327363		1992-06-30	DANIEL; Farb M.	
	6	D331258		1992-11-24	TAROZZI; R.A.	
	7	D351996		1994-11-01	KALVELAGE; J.D.	
	8	D372124		1996-07-30	DAMMERS; K.A.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	14323701
Filing Date	07-03-2014
First Named Inventor	UPCHURCH; Guy
Art Unit	3728
Examiner Name	Luan Kim Bui
Attorney Docket Number	11912USO1

9	D525777		2006-08-01	PRIEBE R.N. et al.	
10	D526478		2006-08-15	PRIEBE R.N. et al.	
11	D642789		2011-08-09	COOPER; M.R.	
12	D683950		2013-06-11	ERNSTER J.A. et al.	
13	D691856		2013-10-22	DABNEY-WIGGS M.	
14	4838444		1989-06-13	BITEL; Vincent J.	
15	6622856		2003-09-23	GALLO; Anthony B. et al.	
16	8499531		2013-08-06	BENETRI; Vince et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

Receipt date: 06/02/2015

14323701 - GAU: 3728

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		14323701
Filing Date		07-03-2014
First Named Inventor	UPCHURCH; Guy	
Art Unit	3728	
Examiner Name	Luan Kim Bui	
Attorney Docket Number	11912USO1	

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS							Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵
	1							☐
If you wish to add additional non-patent literature document citation information please click the Add button								Add
EXAMINER SIGNATURE								
Examiner Signature		/Luan K. Bui/ (09/23/2015)				Date Considered		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	14323701
Filing Date	07-03-2014
First Named Inventor	UPCHURCH; Guy
Art Unit	3728
Examiner Name	Luan Kim Bui
Attorney Docket Number	11912USO1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/lisa v. mueller/	Date (YYYY-MM-DD)	2015-06-02
Name/Print	Lisa V. Mueller	Registration Number	38,978

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //l.k.b./

Doc code: IDS

PTO/SB/08a (01-10)

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		14323701	
	Filing Date		07-03-2014	
	First Named Inventor	UPCHURCH; Guy		
	Art Unit	3728		
	Examiner Name	Luam Kim Bui		
	Attorney Docket Number	11912USO1		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6273260		2001-08-14	COLDEPIETRO; Ralph et al.	
	2	6659280		2003-12-09	PALIOTTA; Michael et al.	
	3	7360652		2008-04-22	ARNOLD; William	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030042167		2003-03-06	BALZ; Eric R. et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1481914	EP	A1	2004-12-01	BRINGHIGH LTD [GB]		☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	14323701
Filing Date	07-03-2014
First Named Inventor	UPCHURCH; Guy
Art Unit	3728
Examiner Name	Luam Kim Bui
Attorney Docket Number	11912USO1

If you wish to add additional Foreign Patent Document citation information please click the Add button **Add**

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	International Search Report and Written Opinion for Application No. PCT/US2014/045459, mailed on 03 November 2014, 18 pages.	☐

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	/Luan K. Bui/ (09/23/2015)	Date Considered	
--------------------	----------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	14323701
Filing Date	07-03-2014
First Named Inventor	UPCHURCH; Guy
Art Unit	3728
Examiner Name	Luam Kim Bui
Attorney Docket Number	11912USO1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/lisa m. mueller/	Date (YYYY-MM-DD)	2015-04-27
Name/Print	Lisa M. Mueller	Registration Number	38,978

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

[TRADUCCIÓN]

OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS

DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS

Oficina de Patentes y Marcas de los Estados Unidos

Domicilio: Sr. Comisario de Patentes, P. O. Box 1450. Alexandria, Virginia

22313-1450. www.uspto.gov

AVISO DE ACEPTACIÓN Y ARANCELES

17567 7590 30/09/2015

Señores

Michael Best & Friedrich LLP (AbbVie).

Two Prudential Plaza

180 North Stetson Avenue, Suite 2000

Chicago, IL 60601

EXAMINADOR: BIU, LUAN KIM

UNIDAD TÉCNICA: 3728

FECHA DE ENVÍO: 30/09/2015

Nro. de solicitud: 14/323.701

Fecha de presentación: 07/03/2014

Primer inventor nombrado: Guy Upchurch

Nro. de expediente del agente: 031777-1823-06/11912USO1

Nro. de confirmación: 4322

Título de la invención: **Envase de medicamento, método para ensamblar el envase y método para dispensar el medicamento del envase**

Tipo de solicitud: no provisional

Pequeña empresa: Sin descuento

Tasa de concesión a pagar: \$960

Tasa de publicación a pagar: \$0

Tasa prepagada: \$0

Total de aranceles a pagar: \$960

Fecha de vencimiento: 30/12/2015

La solicitud anteriormente identificada ha sido examinada y se ha autorizado su emisión como patente. Se da por concluido el examen de fondo. El presente aviso de autorización no es una concesión de derechos de patente. Esta solicitud puede ser retirada de su emisión por iniciativa de la oficina o a solicitud del solicitante. Véase el art. 1313 del Título 37 del Código Federal de Regulaciones (CFR) y el art. 1308 del Manual de Procedimiento de Examen de Patentes (MPEP).

La tasa de emisión y la tasa de publicación (si se solicita) se deben pagar dentro de los tres meses de la fecha de envío por correo de la presente notificación; de lo contrario, esta solicitud se dará por abandonada. Este plazo legal no se puede prorrogar. Véase el art. 151 del Título 35 del Código de Estados Unidos (USC). La tasa de emisión a pagar que se indica precedentemente no refleja un crédito por tasas de emisión previamente pagadas en esta solicitud. Si se han pagado previamente tasas de emisión en esta solicitud (según se indica precedentemente), se considerará la devolución de la parte B de este formulario sea devuelta a solicitud de que se apliquen las tasas previamente pagadas al pago a realizar.

Cómo responder a esta notificación:

I. Verifique el casillero de PEQUEÑA EMPRESA que aparece arriba. Si en el

casillero "tipo de entidad" figura "pequeña" o "micro" empresa, verifique si dicha calificación aún se aplica al solicitante.

Si dicho "tipo de entidad" indicado coincide con el actual, sírvase abonar el TOTAL DE TASAS A PAGAR que se indica arriba.

Si dicho tipo de entidad se ha modificado, respecto de lo informado más arriba, en la PARTE B – TRANSFERENCIA DEL ARANCEL O ARANCELES, complete la sección 5 titulada "Cambio del tipo de entidad (del tipo que se indica más arriba)"

A los efectos de este aviso, los aranceles de pequeñas empresas son $\frac{1}{2}$ de la suma de los aranceles no descontados, y los aranceles de las micro empresas son $\frac{1}{2}$ de la suma de los aranceles de las pequeñas empresas.

II. El formulario Transferencia del arancel de emisión - Parte B se debe completar y presentar en la Oficina de Patentes y Marcas junto con la TASA DE EMISIÓN y la TASA DE PUBLICACIÓN (si se solicita). Si ha optado por cancelar el pago mediante un débito a su cuenta de depósito, debe completar la sección 4b del formulario y presentar una copia adicional del formulario. Si se presenta un equivalente de la Parte B, se debe indicar expresamente que se solicita la aplicación del pago de la tasa de emisión previamente realizado, y pueden producirse demoras en el trámite a causa de la dificultad de reconocer al documento como un equivalente de la Parte B.

III. Todas las comunicaciones relativas a esta solicitud deben llevar el Nro. de solicitud. Se ruega dirigir todas las comunicaciones previas a la emisión a "Stop ISSUE FEE" salvo que se indique lo contrario.

IMPORTANTE: las patentes de utilidad emitidas en virtud de solicitudes presentadas desde el 12 de diciembre de 1980 inclusive pueden ser pasibles

del pago de anualidades. Es responsabilidad de quien tramita la patente verificar el pago el término de dichas anualidades.

Señores

Michael Best & Friedrich LLP (AbbVie).

Two Prudential Plaza

180 North Stetson Avenue, Suite 2000

Chicago, IL 60601

Nro. de solicitud: 14/323.701

Fecha de presentación: 07/03/2014

Primer inventor nombrado: Guy Upchurch

Nro. de expediente del agente: 031777-1823-06/11912USO1

Nro. de confirmación: 4322

Título de la invención: **Envase de medicamento, método para ensamblar el envase y método para dispensar el medicamento del envase**

Tipo de solicitud: no provisional

Pequeña empresa: Sin descuento

Tasa de concesión a pagar: \$960

Tasa de publicación a pagar: \$0

Tasa prepagada: \$0

Total de aranceles a pagar: \$960

Fecha de vencimiento: 30/12/2015

EXAMINADOR: BIU, LUAN KIM

UNIDAD TÉCNICA: 3728

CLASE-SUBCLASE 206-531000

Determinación del Plazo de Concesión según el art. 154 (b) del Título 35 del USC

(Solicitudes presentadas a partir del 29 de mayo de 2000)

La Oficina ha dejado de proporcionar un cálculo del ajuste en la duración de la patente (PTA) con el aviso de concesión.

El artículo 1(h)(2) de la Ley de Correcciones Técnicas de Invenciones de los Estados Unidos Leahy-Smith modificada por el art. 154(b)(3)(B)(i) del Título 35 del USC para eliminar el requisito de que la Oficina proporcione una determinación del ajuste en la duración de la patente con el aviso de aceptación. Véase Revisiones del ajuste en la duración de la patente, páginas 19416 y 19417 del Tomo 78 del Registro Federal (1 de abril de 2013). Por lo tanto, la Oficina ha dejado de facilitar la determinación inicial del ajuste en la duración de la patente en la carta de aviso de emisión que se envía por correo al solicitante aproximadamente tres semanas antes de la fecha de emisión de la patente, e incluirá el ajuste en la duración de la patente en la misma patente. Las solicitudes de reconsideración de la determinación del ajuste en la duración de la patente (o el restablecimiento del ajuste en la duración de la patente) deben seguir el procedimiento descrito en el art. 1.705 del Título 37 del CFR.

Cualquier pregunta relativa a la prórroga de la duración de la patente o al ajuste de la determinación de plazos deberá dirigirse a: Patent Legal Administration (571)-272-7702. Las preguntas relativas a las tasas de emisión se deberán dirigir a: Customer Service Center of the Office of Patent Publication en los teléfonos 1-(888)-786-0101 o (571)-272-4200

Aviso en el que se requiere el juramento o la declaración del inventor

Solicitud Nro.:14/323.701

Solicitante: Guy Upchurch

Examinador: BIU, LUAN KIM

Unidad Técnica: 3728

Este aviso se adjunta al aviso de admisibilidad (PTOL-37), o al aviso de admisibilidad de una solicitud de diseño (POOL-37D).

El juramento o declaración de un inventor de conformidad con los arts. 1.63 o 1.64 del Título 37 del CFR de cada inventor o con respecto a cada uno de ellos aún no ha sido presentado.

El juramento o declaración de conformidad con el art. 1.63 del Título 37 del CFR o una declaración sustitutiva de conformidad con el art. 1.64 del Título 37 del CFR, de cada inventor o con respecto a cada uno de ellos (en el caso de que el juramento, declaración o declaración sustitutiva aún no haya sido presentado) DEBE ser presentado a más tardar en la fecha en que se haya abonado la tasa de emisión. Véase el art. 115 (f) del Título 35 USC. La falta de cumplimiento oportuno dará lugar al ABANDONO de esta solicitud.

El juramento o la declaración requerido al inventor no ha sido recibido del siguiente/siguientes inventor(es):

Si el solicitante presentó previamente uno o más juramentos, declaraciones o declaraciones sustitutivas, el solicitante puede haber recibido un aviso en el que se le informan las deficiencias en el mismo.

Se observaron las siguientes deficiencias:

PROBLEMAS FORMALES

* No se ha recibido la declaración jurada del inventor parte de los siguientes

inventores: **Guy Upchurch y John G. Finch.**

El solicitante podrá presentar la declaración jurada del inventor en cualquier momento antes de que el aviso de aceptación y arancel(es) debidos, PTOL 85, sea enviado por correo.

Las dudas relacionadas con este aviso podrán consultarse en Application Assistance Unit llamando al número de teléfono 571-272-4200

Autorización de la OMB y Declaración obligatoria de la PRA para la Parte B de PTOL 85

La Ley de Reducción de Trámites (PRA) de 1995 requiere que los organismos federales obtengan la autorización de la Oficina de Administración y Presupuesto (OMB) antes de solicitar la mayoría de los diferentes tipos de información del público. Cuando la OMB aprueba una solicitud de un organismo para recopilar información del público, la OMB (i) provee un número de control y una fecha de vencimiento válida de la OMB para que el organismo los incluya en el instrumento que se utilizará para recopilar la información y (ii) requiere que el organismo informe al público acerca del significado legal del número de control de la OMB de acuerdo con el art. 1320.5(b) del Título 5 del CFR.

La información recopilada en virtud de la Parte B de PTOL 85 es requerida por el art. 1.311 del Título 37 del CFR. La información es necesaria para obtener o conservar un beneficio por parte del público que presente una solicitud (que la USPTO tramitará). La confidencialidad se rige por el art. 122 del Título 35 del USC y el art. 1.14 del Título 37 del CFR. Se estima que el llenado de esta solicitud insume 12 minutos, incluida la recopilación, preparación y envío de la solicitud completada a la USPTO. El tiempo variará según diferencias individuales. Todo comentario referido al tiempo requerido para completar este formulario y/o sugerencias que puedan facilitar su llenado podrán ser enviados a Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. NO ENVIAR ARANCELES O DOCUMENTOS CON INFORMACIÓN A ESTA DIRECCIÓN, LOS MISMOS DEBEN ENVIARSE A: Commissioner for Patents, P.O. Box

1450, Alexandria, Virginia 22313-1450. En virtud de la Ley de Reducción de Trámites de 1995, ninguna persona está obligada a responder a una solicitud de información salvo que la misma contenga un número de control válido de la OMB.

LEY DE PRIVACIDAD

La Ley de Privacidad de 1974 (P.L. 93-579) requiere que se provea cierta información en relación con la presentación del formulario adjunto relacionado con una solicitud de patente o patente, de acuerdo con lo requerido por la Ley, le informamos que: (1) la fuente de la recopilación de esta información es el art. 2(b) del Título 35 del U.S.C.; (2) la presentación de la información es voluntaria; y (3) el propósito principal para el cual la Oficina de Patentes de los EE. UU. utilizará esta información es procesar y/o examinar la presentación de una solicitud de patente o patente, si no se presentara la información requerida, existe la posibilidad de que a la Oficina de Patentes y Marcas no le sea posible procesar y/o examinar la presentación, lo cual puede tener como consecuencia la finalización del trámite o el abandono de la solicitud o expiración de la patente.

La información provista por el solicitante en el presente formulario está destinada normalmente a lo siguiente:

1. La información del presente formulario recibirá tratamiento confidencial en la medida que lo permita la Ley de Libertad de Información (art. 552 del Título 5 del U.S.C.) y la Ley de Privacidad (art. 552a del Título 5 del U.S.C.), Los contenidos provenientes del sistema del registro pueden ser revelados al Departamento de Justicia a fin de determinar si la revelación de estos registros es requerida por la Ley de Libertad de Información;

2. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros en el curso de la presentación de pruebas ante un tribunal, juez o tribunal administrativo, incluyendo revelaciones al abogado de la otra parte en el curso de las negociaciones de un acuerdo extrajudicial;
3. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a un legislador que presente una solicitud con referencia a un individuo al cual pertenecen los registros, cuando dicho individuo haya solicitado la colaboración del legislador con respecto al asunto al cual se refiere el registro;
4. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a un contratista de una Agencia que necesite de tal información a fin de redactar un contrato. Las personas que reciban la información deberán cumplir los requisitos de la Ley de Privacidad de 1974, según sus modificaciones, de acuerdo con el art. 552a(m) del Título 5 del U.S.C.;
5. Como procedimiento de rutina, es posible revelar a la Oficina de la Organización de la Propiedad Intelectual Mundial, una Solicitud Internacional presentada a tenor de lo dispuesto en el Tratado de Cooperación en Patentes que se encuentre en este sistema
6. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a otra dependencia federal para revisión por motivos de Seguridad Nacional (art. 181 del Título 35 del U.S.C) y para revisión de acuerdo con la Ley de Energía Atómica (art. 218 (c) del Título 42 del U.S.C.;
7. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al Administrador de Servicios Generales (GSA) o a la persona designada por el mismo, durante una inspección de los registros realizada por

la GSA como parte de la responsabilidad de la institución de recomendar mejoras en las prácticas de manejo de los registros y programas, de acuerdo con los arts. 2904 y 2906 del Título 44 del U.S.C., tales revelaciones se realizarán de acuerdo con las leyes de GSA que rigen la inspección de registros con dicho propósito y otras directivas pertinentes (es decir, GSA o Comercio), tales revelaciones no serán utilizadas para dictar resoluciones con respecto a individuos;

8. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al público luego de la publicación de la solicitud de acuerdo con el art. 122(b) del Título 35 del U.S.C. o de la emisión de una patente de acuerdo con el art. 151 del Título 35 del U.S.C., Además, normalmente es posible revelar al público un registro, con las limitaciones impuestas por el art. 114 del Título 37 del CFR, si el registro fue presentado en una solicitud luego abandonada o cuya tramitación ha finalizado y que es mencionada como referencia por una solicitud publicada, una solicitud abierta a la inspección del público o una patente emitida;

9. Como procedimiento de rutina, es posible que se revele un registro de este sistema de registros a una organismo de control o judicial, federal o municipal si la USPTO considera que existe una violación o posible violación de una ley o reglamento.

Notificación de posibilidad de autorización de emisión:

Número de solicitud: 14/323.701

Examinador: Luan K. Bui

Solicitante: UPCHURCH y otros

Unidad Técnica: 3728

Estado de AIA (Primer inventor en presentar): Sí

La **FECHA DE ENVÍO POR CORREO** de la comunicación aparece en la portada junto con la dirección postal. Al aceptarse todas las reivindicaciones, se **CIERRA** o no se reabre el **EXAMEN DE FONDO** de la solicitud. Si no se adjunta al presente (o fuera enviado por correo) se enviará por correo una Notificación de autorización de emisión (PTOL - 85) u otra comunicación pertinente. El presente aviso de **AUTORIZACIÓN DE EMISIÓN** no debe interpretarse como la **CONCESIÓN DE DERECHOS DE PATENTE**. La presente solicitud puede ser retirada por iniciativa de la Oficina de Patentes y Marcas o a pedido del solicitante a fin de que no se produzca la emisión. Véase el art. 1.13 del Título 37 del CFR y el art. 1308 del MPEP .

1. La presente comunicación se cursa en respuesta a la efectuada el 7/03/2014

3. Las reivindicaciones aceptadas son 1, 2, 4-9,11-14 y 24-33. Como resultado de las reivindicaciones aceptadas, el solicitante puede ser seleccionado como beneficiario del programa de la autopista de trámites de patentes en una oficina de propiedad intelectual para la solicitud respectiva. Para obtener más información, consultar en http://www.uspto.gov/patents/init_events/pph/index.jsp o enviar una consulta a PPHfeedback@uspto.gov

Adjuntos

1. Aviso de referencias citadas (PTO-892)
2. Declaraciones de divulgación de información (PTO/SB/08).

/Luan K. Bui/

Examinador primario

Unidad Técnica: 3728

Hoja complementaria (PTOL 37)

Nro. de Solicitud: 14/323.701

Continuación de adjunto(s) 2. Declaraciones de divulgación de información (PTO/SB/08), Documento Nro./Fecha de envío por correo: 09/10/14; 27/4/15; 2/6/15.

Aviso de referencias citadas

Nro. de solicitud/control: 14/323.701.

Solicitante/ patente bajo reexaminación: UPCHURCH y otros

Examinador: Luan K. Bui

Unidad Técnica: 3728

DOCUMENTOS DE PATENTE DE LOS ESTADOS UNIDOS.

*		Nro. de doc. Código de país- nro-tipo de código	Fecha MM-AAAA	Nombre	Clasificación
*	A	US-3.921.804A	11-1975	Tester; William W.	206/531
*	B	US-5.109.984A	05-1992	Romick; Jerome M.	206/531
*	C	US-5.489.025A	02-1996	Romick; Jerome M.	206/531
*	D	US-6.082.544A	07-2000	Romick; J. M.	206/531
*	E	US- 2003/0042167A1	03-2003	Balz, Eric R.	206/531
*	F	US- 2006/0163110A1	07-2006	Adler; Deborah B.	206/534
*	G	US- 2009/0301924A1	12-2009	Rondeau; Gilles	206/531
*	H	US-7.748.535B	07-2010	Grosskopf;	206/531

				Glenn A.	
*	I	US- 2012/0261275A1	10-2012	Intini; Derak	206/532
*	J	US-8.757.381B2	06-2014	Bouthiette; Michael	206/528

DECLARACIÓN DE DIVULGACIÓN DE INFORMACIÓN DEL SOLICITANTE**(No para presentar de conformidad con el art. 1.99 del Título 37 del CFR)**

Nro. de Solicitud: 14323701

Fecha de presentación: 03-07-2014

Primer inventor mencionado: Guy Upchurch

Unidad Técnica: 3728

Nombre del examinador: Aún no informado

Nro. de Expediente del Agente: 031777-1823-06

PATENTES DE EE. UU.						Eliminar
Iniciales del examinador *	Cita Nro.	Número de patente	Código o de Tipo ₁	Fecha de emisión	Nombre del titular de la patente o del solicitante del documento citado	Páginas, columnas, líneas donde aparecen los pasajes o las figuras pertinentes
	1.	RE29705		1978-07-18	Compere	
	2.	3288281		1966-11-29	Sparks	
	3.	3305077		1967-02-21	Greif y otros.	
	4.	4120400		1978-10-17	Kotyuk	
	5.	4192422		1980-03-11	Kotyuk	
	6.	4340141		1982-07-20	Fischer	
	7.	5050739		1991-09-24	Hannan y otros	
	8.	5740717		1998-04-21	Sowden y otros.	

	9.	6138830		2000-10-31	Muggli	
	10.	6138830		2000-10-31	Muggli	
	11.	6443307		2002-09-03	Burridge	
	12.	6516949		2003-02-11	Fuller y otros.	
	13.	6679382		2004-01-20	Kancsar y otros.	
	14.	6793077		2004-09-21	Kancsar y otros.	
	15.	6896139		2005-05-24	Kancsar y otros.	
	16.	6997320		2006-02-14	Kancsar y otros.	
	17.	7063211		2006-06-20	Williams- Hartman	
	18.	7126879		2006-10-24	Snyder	
	19.	7188728		2007-03-13	Williams- Hartman	
	20.	7641050		2010-01-05	Klatt y otros.	
	21.	7665610		2010-02-23	Williams- Hartman	
	22.	7696236		2010-04-13	Bradford	
	23.	7748535		2010-07-06	Grosskopf	
	24.	7767700		2010-08-03	Bradford	
	25.	7784250		2010-08-31	Grosskopf	
	26.	7900772		2011-03-08	Sack y otros.	

	27.	7905355		2011-03-15	Williams-Hartman	
	28.	7926660		2011-04-19	Jones y otros.	
	29.	7967144		2011-06-28	Sack y otros.	
	30.	7997411		2011-08-16	Williams-Hartman	
	31.	8132671		2012-03-13	Hession	
	32.	8205752		2012-06-26	Sack y otros.	
	33.	8342330		2013-01-01	Weston y otros.	
	34.	8342331		2013-01-01	Ziemba y otros.	
	35.	8403212		2013-03-26	van Esch	
	36.	8413813		2013-04-09	Grosskopf	
	37.	8420674		2013-04-16	Bradford	
	38.	8479921		2013-07-09	Ingraham	
	39.	8544650		2013-10-01	Williams-Hartman	
	40.	8550248		2013-10-08	Busen	
	41.	8556077		2013-10-15	Hanley	
	42.	8561798		2013-10-22	Hession	
	43.	8567606		2013-10-29	Bellamah y otros.	
	44.	8573403		2013-11-05	Stevens y otros.	

	45.	8579106		2013-11-12	Naik y otros_	
	46.	8584857		2013-11-19	Ozawa y otros.	
	47.	8602218		2013-12-10	Grosskopf	
	48.	8607982		2013-12-17	Jones	
	49.	8607983		2013-12-17	Niven y otros.	
	50.	8627957		2014-01-14	Ziernba y otros.	
	51.	8640917		2014-02-04	Kracke	
	52.	8672134		2014-03-18	Sprada y otros.	
	53.	8740003		2014-06-03	Elliott	
	54.	8746454		2014-06-10	Doucet y otros.	
	55.	8752704		2014-06-17	Leon Alonso y otros.	
	56.	8757381		2014-06-24	Bouthiette	
	57.	D263559		1982-03-30	Poore	
	58.	D293887		1988-01-26	Webster	
	59.	D320930		1991-10-22	Richards	
	60.	D322400		1991-12-17	Sorensen	
	61.	D322934		1992-01-07	Kalvelage	
	62.	D350478		1994-09-13	Fuller y otros.	
	63.	D351995		1994-11-01	Kalvelage	

	64.	D370414		1996-06-04	Lambelet, Jr.	
	65.	D370625		1996-06-11	Kelsey y otros.	
	66.	D372867		1996-08-20	Lambelet, Jr	
	67.	D382474		1997-08-19	Malmborg	
	68.	D404641		1999-01-26	Kelsey y otros.	
	69.	D411445		1999-06-22	Anderson	
	70.	D414106		1999-09-21	Anderson	
	71.	D457246		2002-05-14	Mami y otros	
	72.	D480958		2003-10-21	Mazel y otros.	
	73.	D518737		2006-04-11	Zalzal	
	74.	D546198		2007-07-10	Currie y otros.	
	75.	D558603		2008-01-01	Priebe y otros.	
	76.	D622158		2010-08-24	Proulx	
	77.	D637391		2011-05-10	Stevens y otros.	
	78.	D650295		2011-12-13	Schmitz y otros.	
	79.	D658991		2012-05-08	Schmitz y otros.	
	80.	D659019		2012-05-08	Specker y otros.	
	81.	D659550		2012-05-15	Mazor	

	82.	D670178		2012-11-06	Carson	
	83.	D684482		2013-06-18	Stevens	
	84.	D685272		2013-07-02	Stevens	
	85.	D688570		2013-08-27	Logue	
	86.	D688571		2013-08-27	Logue	
	87.	D689373		2013-09-10	Logue	
	88.	D689374		2013-09-10	Logue	
	89.	D689778		2013-09-17	Logue	
	90.	D691465		2013-10-15	O'Brien y otros.	
	91.	D711219		2014-08-19	Palsson	

Si desea agregar información adicional de citas de patentes de EE. UU. haga clic en el botón Agregar						Add
PUBLICACIONES DE SOLICITUDES DE PATENTES DE EE. UU.						Eliminar
Iniciales del examinador*	Cita Nro.	Número de patente	Código de Tipo ₁	Fecha de emisión	Nombre del titular de la patente o del solicitante del documento citado	Páginas, columnas, líneas donde aparecen los pasajes o las figuras pertinentes
	1	20030034271		2003-02-20	Burridge	
	2	20030164380		2003-09-	Taneja y	

				04	otros.	
	3	20070185615		2007-08-09	Bossi y otros.	
	4	20090038982		2009-02-12	Doucet e1 al.	
	5	20090242451		2009-10-01	Kessler	
	6	20110215022		2011-09-08	Sack y otros.	
	7	20120248005		2012-10-04	Bergey	
	8	20130008825		2013-01-10	McArthur y otros.	
	9	20130193029		2013-08-01	Weston y otros.	
	10	20130220870		2013-08-29	Grosskopf	
	11	20130220871		2013-08-29	Bradford	
	12	20130233756		2013-09-12	Weston y otros.	
	13	20130256183		2013-10-03	Ingraham	
	14	20130281960		2013-10-24	Hanley	

	15	20130306511		2013-11-21	Branyon y otros.	
	16	20140001194		2014-01-02	Pipes y otros.	
	17	20140027340		2014-01-30	Hession	
	18	20140027341		2014-01-30	Ludwig y otros.	
	19	20140083900		2014-03-27	Ziernba y otros.	
	20	20140171436		2014-06-19	Kamen y otros.	
	21	20140183095		2014-07-03	Choubey y otros.	
	22	20140209498		2014-07-31	Stevens	
	23	20140214438		2014-07-31	Ahmadi	
	24	20140216968		2014-08-07	Wagner y otros.	
	25	20140216977		2014-08-07	Bowers y otros.	

Si desea agregar información adicional de citas de Solicitudes Publicadas de EE. UU. haga clic en el botón Agregar	Add
--	-----

DOCUMENTOS DE PATENTES EXTRANJERAS						Eliminar		
Iniciales del examinador*	Cita Nro.	Nro. de Documento Extranjero2	Código de País2	Código de Tipo4	Publication Date	Nombre del titular de la patente o del solicitante del documento citado	Páginas, columnas, líneas donde aparecen los pasajes o las figuras pertinentes	Ts
	1	1211191	EP		2002-05-06	Magnafarma B.V.		☐
	2	2005120984	WO		2005-12-22	Pillot y otros.		☐
	3	2010015638	WO		2010-02-11	N.V. Organon		☐
	4	2014057967	WO		2014-04-17	Astellas Pharma Inc		☐
	5	2014085625	WO		2014-06-05	Meadwestvaco Corp		☐

Si desea agregar información adicional de citas de Documentos de Patentes Extranjeras haga clic en el botón Agregar						Add		
DOCUMENTOS DE PATENTES EXTRANJERAS						Eliminar		
Iniciales del examinador*	Cita Nro.	Incluya el nombre del autor (en MAYÚSCULAS), título del artículo (cuando corresponda), título del ítem (libro, revista, diario, publicaciones por entregas, ensayos, catálogo, etc.), fecha, página(s), número de volumen-edición, editorial, ciudad y/o país donde se publicó						Ts
	1	Japanese Office action for Design Application No. 2014-7622 dated April 22, 2014. (1 page)						☐

	2	Acción Oficial de la Oficina Japonesa para la Solicitud de Diseño Nro . 2014-7623 de fecha 22 de abril de 2014. (1 <i>pág</i>)	☐
--	---	---	--------------------------

FIRMA DEL EXAMINADOR			
Firma del examinador	/Luan K. Bui/ (23/09/2015)	Fecha de consideración	
*EXAMINADOR: Inicialar si la referencia inicial es tenida en cuenta, esté o no la cita en conformidad con el art. 609 de la MPEP. Trace una línea sobre una cita si no está en conformidad y no se la tiene en cuenta. Incluya una copia de este formulario con la siguiente comunicación al solicitante.			
'Véanse los códigos de tipo de documentos de patente de la USPTO en www.USPTO.GOV o el art. 901.04 del MPEP. Indique la oficina que emitió el documento, con el código de dos letras (Norma ST.3 de la OMPI).³ En el caso de documentos de patentes japonesas, la indicación del año del reinado del emperador debe preceder el número de serie del documento de la patente. ⁴ Si es posible, indique el tipo de documento con los símbolos adecuados como se indica en el documento en virtud de la Norma ST-16 de la OMPI.⁵ El solicitante debe colocar una marca aquí si se adjunta una traducción en idioma inglés.			

DECLARACIÓN DE CERTIFICACIÓN

Véanse los arts. 1.97 y 1.98 del Título 37 del CFR para hacer la selección o selecciones adecuada(s).

X No se acompaña una declaración de certificación en el presente documento.

Firmas

Se requiere la firma del solicitante o del representante de acuerdo con los arts. 1.33, 10.18 del CFR. Véase el art 1.4 (d) del Título 37 del CFR con referencia al formato de la firma.

Firma	/julie a. haul/	Fecha:	09-10-2014
Nombre:	Julie A. Haul	Número de matrícula:	51.789

Esta información es requerida por los arts. 1.97 y 1.98 del Título 37 del CFR. La misma es requerida para la obtención o mantenimiento de un beneficio relacionado con la presentación de una solicitud (y su procesamiento por parte de USPTO). La confidencialidad se rige por el art 122 del Título 35 del USC y el art. 1.14 del Título 37 del CFR. Se estima que el llenado del formulario insume 23 minutos. El tiempo variará según diferencias individuales. Cualquier comentario referido al tiempo requerido para completar este formulario y/o sugerencias que puedan facilitar su llenado podrán ser enviados a Chief Information Officer, US Patent and Trademark Office. US Department of Commerce; PO Box 1450, Alexandria Va 22313-1450. No enviar aranceles o documentos con información a esta dirección, los mismos deben enviarse a: Commissioner for Patents, PO Box 1450 Alexandria VA 22313-1450.

LEY DE PRIVACIDAD

La Ley de Privacidad de 1974 (P.L. 93-579) requiere que se provea cierta información en relación con la presentación del formulario adjunto relacionado con una solicitud de patente o patente, De acuerdo con lo requerido por la Ley, le informamos que: (1) la autoridad general con respecto a la recopilación de esta información es U.S.C. 35 2 (b); (2) la presentación de la información es voluntaria; y (3) el propósito principal para el cual la Oficina de Patentes de los EE UU utilizará esta información es procesar y/o examinar la presentación de una solicitud de patente o patente, Si no se presentara la información requerida, existe la posibilidad de que a la Oficina de Patentes y Marcas no le sea posible procesar y/o examinar la presentación, lo cual puede tener como consecuencia la finalización de los procedimientos o el abandono de la solicitud o expiración de la patente.

La información provista por el solicitante en el presente formulario está destinada normalmente a lo siguiente:

1. La información del presente formulario recibirá tratamiento confidencial en la medida que lo permita la Ley de Libertad de Información (552 del U.S.C. 5) y Ley de Privacidad (552a del U.S.C. 5), Los contenidos provenientes del sistema del registro pueden ser revelados al Departamento de Justicia a fin de determinar si la revelación de estos registros es requerida por la Ley de Libertad de Información;
2. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros en el curso de la presentación de evidencia a una corte, magistrado o tribunal administrativo, incluyendo revelaciones al abogado oponente en el curso de las negociaciones;

3. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a un miembro de Congreso que presente una solicitud con referencia a un individuo al cual pertenecen los registros, cuando dicho individuo ha solicitado la colaboración del Miembro del Congreso con respecto al asunto al cual se refiere el registro;
4. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al un contratista de una Agencia que necesite de tal información a fin de redactar un contrato, Las personas que reciben la información deberán cumplir los requerimientos de la Ley de Privacidad de 1974, según sus enmiendas, de acuerdo con 552^a (m) del U.S.C.5;
5. Como procedimiento de rutina, es posible revelar a la Oficina de la Organización de la Propiedad Intelectual Mundial, una Solicitud Internacional presentada bajo el Tratado de Cooperación en Patentes que se encuentre en este sistema, de acuerdo con el Tratado de Cooperación en Patentes;
6. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a otra dependencia federal para revisión por motivos de Seguridad Nacional (181 U.S.C 35) y para revisión de acuerdo con la Ley de Energía Atómica (218 (c) U.S.C. 42;
7. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al Administrador de Servicios Generales o la persona designada por el mismo, durante una inspección de los registros realizada por GSA como parte de la responsabilidad de la institución de recomendar mejoras en las prácticas de manejo de los registros y programas, de acuerdo con 2904 y 2906 del U.S.C. 44, Tales revelaciones se realizarán de acuerdo con las leyes de GSA que gobiernan la inspección de registros con dicho propósito y otras

directivas pertinentes (es decir, GSA o Comercio), Tales revelaciones no serán utilizadas para efectuar resoluciones con respecto a individuos;

8. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al público luego de la publicación de la solicitud de acuerdo con 122(b) del U.S.C. 35 o de la emisión de una patente de acuerdo con 151 del U.S.C. 35, Además, normalmente es posible revelar al público un registro, con las limitaciones impuestas por 1,14 del CFR 37, si el registro fue presentado en una solicitud luego abandonada o cuya tramitación ha finalizado y que es mencionada como referencia por una solicitud publicada, una solicitud abierta a la inspección del público o una patente emitida;

9. Como procedimiento de rutina, es posible que se revele un registro de este sistema de registros a una entidad reguladora o judicial, federal o local si la USPTO considera que existe una violación o violación potencial de una ley o reglamento.

DECLARACIÓN DE DIVULGACIÓN DE INFORMACIÓN DEL SOLICITANTE**(No para presentar de conformidad con el art. 1.99 del Título 37 del CFR)**

Nro. de Solicitud: 14323701

Fecha de presentación: 03-07-2014

Primer inventor mencionado: Guy Upchurch

Unidad Técnica: 3728

Nombre del examinador: Luan Kim Bui

Nro. de Expediente del Agente: 11912USO1

PATENTES DE EE. UU.						Eliminar
Iniciales del examinador *	Cita Nro.	Número de patente	Código o de Tipo ₁	Fecha de emisión	Nombre del titular de la patente o del solicitante del documento citado	Páginas, columnas, líneas donde aparecen los pasajes o las figuras pertinentes
	1.	D254219		1980-02-19	PAPCIAK; W.G.	
	2.	D261198		1981-10-31	ALTADONNA ; J.	
	3.	D268130		1983-03-01	EASTON; H.J.	
	4.	D276116		1984-10-30	BASIL M.E. y otros.	
	5.	D327363		1992-06-30	DANIEL; Farb	

					M.	
	6.	D331258		1992-11-24	TAROZZI; R.A.	
	7.	D351996		1994-11-01	KALVELAGE; JD	
	8.	D372124		1996-07-30	DAMMERS: K.A.	
	9.	D525777		2006-08-01	PRIEBE R.N. y otros.	
	10.	D526478		2006-08-15	PRIEBE R.N. y otros.	
	11.	D642789		2011-08-09	COOPER; M.R.	
	12.	D683950		2013-06-11	ERNSTER J.A. y otros.	
	13.	D691856		2013-10-22	DABNEY- WIGGS M.	
	14.	4838444		1989-06-13	BITEL; Vincent J.	
	15.	6622856		2003-09-23	GALLO; Anthony B. y otros.	
	16.	8499531		2013-08-06	BENETRI; Vince y otros.	

FIRMA DEL EXAMINADOR			
Firma del examinador	/Luan K. Bui/ (23/09/2015)	Fecha de consideración	
*EXAMINADOR: Inicialar si la referencia inicial es tenida en cuenta, esté o no la cita en conformidad con el art. 609 de la MPEP. Trace una línea sobre una cita si no está en conformidad y no se la tiene en cuenta. Incluya una copia de este formulario con la siguiente comunicación al solicitante.			
'Véanse los códigos de tipo de documentos de patente de la USPTO en www.USPTO.GOV o el art. 901.04 del MPEP. Indique la oficina que emitió el documento, con el código de dos letras (Norma ST.3 de la OMPI).³ En el caso de documentos de patentes japonesas, la indicación del año del reinado del emperador debe preceder el número de serie del documento de la patente. ⁴ Si es posible, indique el tipo de documento con los símbolos adecuados como se indica en el documento en virtud de la Norma ST-16 de la OMPI.⁵ El solicitante debe colocar una marca aquí si se adjunta una traducción en idioma inglés.			

DECLARACIÓN DE CERTIFICACIÓN

Véanse los arts. 1.97 y 1.98 del Título 37 del CFR para hacer la selección o selecciones adecuada(s).

X No se acompaña una declaración de certificación en el presente documento.

Firmas

Se requiere la firma del solicitante o del representante de acuerdo con el art. 1.33, 10.18 del CFR. Véase el art 1.4 (d) del CFR 37 con referencia al formato de la firma.

Firma	/lisa v. mueller/	Fecha:	02-06-2015
Nombre:	Lisa V. Mueller	Número de matrícula:	38.978

Esta información es requerida por el art. 1.97 y 1.98, 37 del CFR. La misma es requerida para la obtención o mantenimiento de un beneficio relacionado con la presentación de una solicitud (y su procesamiento por parte de USPTO). La confidencialidad se rige por el art 122, 35 del USC y 1.14, 37 del CFR. Se estima que el llenado de la información insume 23 minutos. El tiempo variará según diferencias individuales. Cualquier comentario referido al tiempo requerido para completar este formulario y/o sugerencias que puedan facilitar su ejecución serán enviadas a Chief Information Officer, US Patent and Trademark Office. US Department of Commerce; PO Box 1450, Alexandria Va 22313-1450. No enviar aranceles o documentos con información a esta dirección. Envíense estos a: Commissioner for Patents, PO Box 1450 Alexandria VA 22313-1450.

LEY DE PRIVACIDAD

La Ley de Privacidad de 1974 (P.L. 93-579) requiere que se provea cierta información en relación con la presentación del formulario adjunto relacionado con una solicitud de patente o patente, De acuerdo con lo requerido por la Ley, le informamos que: (1) la autoridad general con respecto a la recopilación de esta información es U.S.C. 35 2 (b); (2) la presentación de la información es voluntaria; y (3) el propósito principal para el cual la Oficina de Patentes de los EE UU utilizará esta información es procesar y/o examinar la presentación de una solicitud de patente o patente, Si no se presentara la información requerida, existe la posibilidad de que a la Oficina de Patentes y Marcas no le sea posible procesar y/o examinar la presentación, lo cual puede tener como consecuencia la finalización de los procedimientos o el abandono de la solicitud o expiración de la patente.

La información provista por el solicitante en el presente formulario está destinada normalmente a lo siguiente:

1. La información del presente formulario recibirá tratamiento confidencial en la medida que lo permita la Ley de Libertad de Información (552 del U.S.C. 5) y Ley de Privacidad (552a del U.S.C. 5), Los contenidos provenientes del sistema del registro pueden ser revelados al Departamento de Justicia a fin de determinar si la revelación de estos registros es requerida por la Ley de Libertad de Información;
2. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros en el curso de la presentación de evidencia a una corte, magistrado o tribunal administrativo, incluyendo revelaciones al abogado oponente en el curso de las negociaciones;

3. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a un miembro de Congreso que presente una solicitud con referencia a un individuo al cual pertenecen los registros, cuando dicho individuo ha solicitado la colaboración del Miembro del Congreso con respecto al asunto al cual se refiere el registro;
4. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al un contratista de una Agencia que necesite de tal información a fin de redactar un contrato, Las personas que reciben la información deberán cumplir los requerimientos de la Ley de Privacidad de 1974, según sus enmiendas, de acuerdo con 552^a (m) del U.S.C.5;
5. Como procedimiento de rutina, es posible revelar a la Oficina de la Organización de la Propiedad Intelectual Mundial, una Solicitud Internacional presentada bajo el Tratado de Cooperación en Patentes que se encuentre en este sistema, de acuerdo con el Tratado de Cooperación en Patentes;
6. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a otra dependencia federal para revisión por motivos de Seguridad Nacional (181 U.S.C 35) y para revisión de acuerdo con la Ley de Energía Atómica (218 (c) U.S.C. 42;
7. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al Administrador de Servicios Generales o la persona designada por el mismo, durante una inspección de los registros realizada por GSA como parte de la responsabilidad de la institución de recomendar mejoras en las prácticas de manejo de los registros y programas, de acuerdo con 2904 y 2906 del U.S.C. 44, Tales revelaciones se realizarán de acuerdo con las leyes de GSA que gobiernan la inspección de registros con dicho propósito y otras

directivas pertinentes (es decir, GSA o Comercio), Tales revelaciones no serán utilizadas para efectuar resoluciones con respecto a individuos;

8. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al público luego de la publicación de la solicitud de acuerdo con 122(b) del U.S.C. 35 o de la emisión de una patente de acuerdo con 151 del U.S.C. 35, Además, normalmente es posible revelar al público un registro, con las limitaciones impuestas por 1,14 del CFR 37, si el registro fue presentado en una solicitud luego abandonada o cuya tramitación ha finalizado y que es mencionada como referencia por una solicitud publicada, una solicitud abierta a la inspección del público o una patente emitida;

9. Como procedimiento de rutina, es posible que se revele un registro de este sistema de registros a una entidad reguladora o judicial, federal o local si la USPTO considera que existe una violación o violación potencial de una ley o reglamento.

DECLARACIÓN DE DIVULGACIÓN DE INFORMACIÓN DEL SOLICITANTE**(No para presentar de conformidad con el art. 1.99 del Título 37 del CFR)**

Nro. de Solicitud: 14323701

Fecha de presentación: 03-07-2014

Primer inventor mencionado: Guy Upchurch

Unidad Técnica: 3728

Nombre del examinador: Luan Kim Bui

Nro. de Expediente del Agente: 11912USO1

PATENTES DE EE. UU.						Eliminar
Iniciales del examinador *	Cita Nro.	Número de patente	Código o de Tipo ₁	Fecha de emisión	Nombre del titular de la patente o del solicitante del documento citado	Páginas, columnas, líneas donde aparecen los pasajes o las figuras pertinentes
	1	6273260		2001-08-14	COLDEPIET RO; y otros.	
	2	6659280		2003-12-09	PALIOTTA; Michael y otros.	
	3	7360652		2008-04-22	ARNOLD; William.	

Si desea agregar información adicional de citas de patentes de EE.	Add
--	-----

UU. haga clic en el botón Agregar						
PUBLICACIONES DE SOLICITUDES DE PATENTES DE EE. UU.						Eliminar
Iniciales del examinador*	Cita Nro.	Número de patente	Código de Tipo ₁	Fecha de emisión	Nombre del titular de la patente o del solicitante del documento citado	Páginas, columnas, líneas donde aparecen los pasajes o las figuras pertinentes
	1	20030042167		2003-03-06	BALZ; Eric R. y otros	

Si desea agregar información adicional de citas de Solicitudes Publicadas de EE. UU. haga clic en el botón Agregar						Add		
DOCUMENTOS DE PATENTES EXTRANJERAS						Eliminar		
Iniciales del examinador*	Cita Nro.	Nro. de Documento Extranjero2	Código de País2	Código de Tipo4	Publication Date	Nombre del titular de la patente o del solicitante del documento citado	Páginas, columnas, líneas donde aparecen los pasajes o las figuras pertinentes	Ts
	1	1481914	EP	A1	2004-12-01	BRINGHIGH LTD (GB)		☐

Si desea agregar información adicional de citas de Documentos de Patentes Extranjeras haga clic en el botón Agregar			Add
DOCUMENTOS DE PATENTES EXTRANJERAS			Eliminar
Iniciales del examinador*	Cita Nro.	Incluya el nombre del autor (en MAYÚSCULAS), título del artículo (cuando corresponda), título del ítem (libro, revista, diario, publicaciones por entregas, ensayos, catálogo, etc.), fecha, página(s), número de volumen-edición, editorial, ciudad y/o país d	Ts
	1	Informe de la Búsqueda Internacional y Opinión Escrita de la Solicitud Nro. PCT/US2014/045459, mailed on 03 November 2014, <i>18 pages</i>	☐

FIRMA DEL EXAMINADOR			
Firma del examinador	/Luan K. Bui/ (23/09/2015)	Fecha de consideración	
*EXAMINADOR: Inicialar si la referencia inicial es tenida en cuenta, esté o no la cita en conformidad con el art. 609 de la MPEP. Trace una línea sobre una cita si no está en conformidad y no se la tiene en cuenta. Incluya una copia de este formulario con la siguiente comunicación al solicitante.			
'Véanse los códigos de tipo de documentos de patente de la USPTO en www.USPTO.GOV o el art. 901.04 del MPEP. Indique la oficina que emitió el documento, con el código de dos letras (Norma ST.3 de la OMPI).³ En el caso de documentos de patentes japonesas, la indicación del año del reinado del emperador debe preceder el número de serie del documento de la patente. ⁴ Si es posible, indique el tipo de documento con los símbolos adecuados como se indica en el documento en virtud de la Norma ST-16 de la OMPI.⁵ El solicitante debe colocar una marca aquí si se adjunta una traducción en idioma inglés.			

DECLARACIÓN DE CERTIFICACIÓN

Véanse los arts. 1.97 y 1.98 del Título 37 del CFR para hacer la selección o selecciones adecuada(s).

X No se acompaña una declaración de certificación en el presente documento.

Firmas

Se requiere la firma del solicitante o del representante de acuerdo con el art. 1.33, 10.18 del CFR. Véase el art 1.4 (d) del CFR 37 con referencia al formato de la firma.			
Firma	/lisa m. mueller/	Fecha:	27-04-2015
Nombre:	Lisa M. Mueller	Número de matrícula:	39.978
Esta información es requerida por el art. 1.97 y 1.98, 37 del CFR. La misma es requerida para la obtención o mantenimiento de un beneficio relacionado con la presentación de una solicitud (y su procesamiento por parte de USPTO). La confidencialidad se rige por el art 122, 35 del USC y 1.14, 37 del CFR. Se estima que el llenado de la información insume 23 minutos. El tiempo variará según diferencias individuales. Cualquier comentario referido al tiempo requerido para completar este formulario y/o sugerencias que puedan facilitar su ejecución serán enviadas a Chief Information Officer, US Patent and Trademark Office. US Department of Commerce; PO Box 1450, Alexandria Va 22313-1450. No enviar aranceles o documentos con información a esta dirección. Envíense estos a: Commissioner for Patents, PO Box 1450 Alexandria VA 22313-1450.			

LEY DE PRIVACIDAD

La Ley de Privacidad de 1974 (P.L. 93-579) requiere que se provea cierta información en relación con la presentación del formulario adjunto relacionado con una solicitud de patente o patente, De acuerdo con lo requerido por la Ley, le informamos que: (1) la autoridad general con respecto a la recopilación de esta información es U.S.C. 35 2 (b); (2) la presentación de la información es voluntaria; y (3) el propósito principal para el cual la Oficina de Patentes de los EE UU utilizará esta información es procesar y/o examinar la presentación de una solicitud de patente o patente, Si no se presentara la información requerida, existe la posibilidad de que a la Oficina de Patentes y Marcas no le sea posible procesar y/o examinar la presentación, lo cual puede tener como consecuencia la finalización de los procedimientos o el abandono de la solicitud o expiración de la patente.

La información provista por el solicitante en el presente formulario está destinada normalmente a lo siguiente:

1. La información del presente formulario recibirá tratamiento confidencial en la medida que lo permita la Ley de Libertad de Información (552 del U.S.C. 5) y Ley de Privacidad (552a del U.S.C. 5), Los contenidos provenientes del sistema del registro pueden ser revelados al Departamento de Justicia a fin de determinar si la revelación de estos registros es requerida por la Ley de Libertad de Información;
2. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros en el curso de la presentación de evidencia a una corte, magistrado o tribunal administrativo, incluyendo revelaciones al abogado oponente en el curso de las negociaciones;

3. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a un miembro de Congreso que presente una solicitud con referencia a un individuo al cual pertenecen los registros, cuando dicho individuo ha solicitado la colaboración del Miembro del Congreso con respecto al asunto al cual se refiere el registro;
4. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al un contratista de una Agencia que necesite de tal información a fin de redactar un contrato, Las personas que reciben la información deberán cumplir los requerimientos de la Ley de Privacidad de 1974, según sus enmiendas, de acuerdo con 552^a (m) del U.S.C.5;
5. Como procedimiento de rutina, es posible revelar a la Oficina de la Organización de la Propiedad Intelectual Mundial, una Solicitud Internacional presentada bajo el Tratado de Cooperación en Patentes que se encuentre en este sistema, de acuerdo con el Tratado de Cooperación en Patentes;
6. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros a otra dependencia federal para revisión por motivos de Seguridad Nacional (181 U.S.C 35) y para revisión de acuerdo con la Ley de Energía Atómica (218 (c) U.S.C. 42;
7. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al Administrador de Servicios Generales o la persona designada por el mismo, durante una inspección de los registros realizada por GSA como parte de la responsabilidad de la institución de recomendar mejoras en las prácticas de manejo de los registros y programas, de acuerdo con 2904 y 2906 del U.S.C. 44, Tales revelaciones se realizarán de acuerdo con las leyes de GSA que gobiernan la inspección de registros con dicho propósito y otras

directivas pertinentes (es decir, GSA o Comercio), Tales revelaciones no serán utilizadas para efectuar resoluciones con respecto a individuos;

8. Como procedimiento de rutina, es posible revelar un registro de este sistema de registros al público luego de la publicación de la solicitud de acuerdo con 122(b) del U.S.C. 35 o de la emisión de una patente de acuerdo con 151 del U.S.C. 35, Además, normalmente es posible revelar al público un registro, con las limitaciones impuestas por 1,14 del CFR 37, si el registro fue presentado en una solicitud luego abandonada o cuya tramitación ha finalizado y que es mencionada como referencia por una solicitud publicada, una solicitud abierta a la inspección del público o una patente emitida;

9. Como procedimiento de rutina, es posible que se revele un registro de este sistema de registros a una entidad reguladora o judicial, federal o local si la USPTO considera que existe una violación o violación potencial de una ley o reglamento.

(12) **United States Patent**
Upchurch et al.

(10) **Patent No.:** **US 9,241,873 B2**
(45) **Date of Patent:** **Jan. 26, 2016**

(54) **MEDICINE CONTAINER, METHOD OF ASSEMBLING THE CONTAINER, AND METHOD OF DISPENSING THE MEDICINE FROM THE CONTAINER**

USPC 206/232, 459.5, 528, 530–532, 534, 206/538, 539, 562–564; 53/467, 468, 473, 53/476, 492; 229/125.125; 493/53, 84, 493/111, 114; 221/25, 28, 31
See application file for complete search history.

(71) Applicant: **AbbVie Inc.**, North Chicago, IL (US)

(72) Inventors: **Guy Upchurch**, North Chicago, IL (US); **John G. Finch**, North Chicago, IL (US)

(73) Assignee: **AbbVie Inc.**, North Chicago, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 16 days.

(21) Appl. No.: **14/323,701**

(22) Filed: **Jul. 3, 2014**

(65) **Prior Publication Data**

US 2015/0014203 A1 Jan. 15, 2015

Related U.S. Application Data

(63) Continuation of application No. 29/488,207, filed on Apr. 16, 2014, now Pat. No. Des. 731,783.

(60) Provisional application No. 61/842,841, filed on Jul. 3, 2013, provisional application No. 61/842,900, filed on Jul. 3, 2013.

(51) **Int. Cl.**
B65D 83/04 (2006.01)
A61J 1/03 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61J 1/035** (2013.01); **A61J 7/0076** (2013.01); **A61J 7/04** (2013.01); **B31B 11/00** (2013.01); **B31B 2201/88** (2013.01); **B31B 2203/103** (2013.01); **B65D 83/0463** (2013.01)

(58) **Field of Classification Search**
CPC B65D 83/0463; A61J 1/035; A61J 7/04; A61J 7/0076; B21B 11/00; B21B 2201/88

(56) **References Cited**

U.S. PATENT DOCUMENTS

D88,285 S 11/1932 Blenker
D189,489 S 12/1960 Jackson et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 314244 S 5/2007
AU 341384 S 3/2012

(Continued)

OTHER PUBLICATIONS

Japanese Office action for Design Application No. 2014-7622 dated Apr. 22, 2014. (1 page).

(Continued)



Primary Examiner — Luan K Bui

(74) *Attorney, Agent, or Firm* — Julie A. Haut; Lisa V. Mueller; Michael Best & Friedrich LLP

(57) **ABSTRACT**

A child-resistant medication container assembly and method of dispensing the medication from the container assembly. The medication container assembly includes a blister pack with a plurality of compartments, each of which supports a medication. The container also includes a puck and a box. The blister pack compartments are aligned with openings on the puck, and the box is configured to receive and secure the puck and the blister pack such that each of the plurality of compartments is aligned with a complementary opening in the box.

20 Claims, 36 Drawing Sheets



(51)	Int. Cl.		7,448,496 B2	11/2008	Williams-Hartman
	A61J 7/00	(2006.01)	D600,503 S	9/2009	Ragsdale et al.
	B31B 11/00	(2006.01)	7,641,050 B2	1/2010	Klatt et al.
	A61J 7/04	(2006.01)	7,665,610 B2	2/2010	Williams-Hartman
(56)	References Cited		7,696,236 B2	4/2010	Bradford
	U.S. PATENT DOCUMENTS		D619,257 S	7/2010	Meschenmoser et al.
	D201,899 S	8/1965 Hancock et al.	D620,260 S	7/2010	Emmert
	D205,676 S	9/1966 Kirwan	7,748,535 B2 *	7/2010	Grosskopf A61J 1/035 206/531
	3,288,281 A	11/1966 Sparks	D622,158 S	8/2010	Proulx
	3,305,077 A	2/1967 Greif et al.	7,767,700 B2	8/2010	Bradford
	3,921,804 A *	11/1975 Tester B65D 83/0463 206/531	7,784,250 B2	8/2010	Grosskopf
	RE29,705 E	7/1978 Compere	7,900,772 B2	3/2011	Sack et al.
	4,120,400 A	10/1978 Kotyuk	7,905,355 B2	3/2011	Williams-Hartman
	D254,219 S	2/1980 Papciak	7,926,660 B2	4/2011	Jones et al.
	4,192,422 A	3/1980 Kotyuk	D637,391 S	5/2011	Stevens et al.
	D261,198 S	10/1981 Altadonna	7,967,144 B2	6/2011	Sack et al.
	D263,559 S	3/1982 Poore	D642,789 S	8/2011	Cooper
	D264,538 S	5/1982 Pomroy et al.	7,997,411 B2	8/2011	Williams-Hartman
	4,340,141 A	7/1982 Fischer	D650,295 S	12/2011	Schmitz et al.
	D266,147 S	9/1982 McIntosh et al.	8,132,671 B2	3/2012	Hession
	D267,767 S	2/1983 Storrs	D658,991 S	5/2012	Schmitz et al.
	D268,130 S	3/1983 Easton	D659,019 S	5/2012	Specker et al.
	D276,116 S	10/1984 Basil et al.	D659,550 S	5/2012	Mazor
	D293,887 S	1/1988 Webster	8,205,752 B2	6/2012	Sack et al.
	4,838,444 A	6/1989 Bitel	D663,981 S	7/2012	Purcell
	5,050,739 A	9/1991 Hannan et al.	D669,311 S	10/2012	Hsu
	D320,930 S	10/1991 Richards	D670,178 S	11/2012	Carson
	D322,400 S	12/1991 Sorensen	D673,297 S	12/2012	Hawker
	D322,934 S	1/1992 Kalvelage	8,342,330 B2	1/2013	Weston et al.
	5,109,984 A *	5/1992 Romick B65D 83/0463 206/531	8,342,331 B2	1/2013	Ziemba et al.
	D327,363 S	6/1992 Farb	8,403,212 B2	3/2013	van Esch
	D331,258 S	11/1992 Tarozzi	8,413,813 B2	4/2013	Grosskopf
	D350,478 S	9/1994 Fuller et al.	8,420,674 B2	4/2013	Bradford
	D351,995 S	11/1994 Kalvelage	D683,950 S	6/2013	Ernster et al.
	D351,996 S	11/1994 Kalvelage	D684,482 S	6/2013	Stevens
	5,489,025 A *	2/1996 Romick A61J 7/0076 206/531	D685,272 S	7/2013	Stevens
	D370,414 S	6/1996 Lambelet, Jr.	8,479,921 B2	7/2013	Ingraham
	D370,625 S	6/1996 Kelsey et al.	D688,570 S	8/2013	Logue
	D372,124 S	7/1996 Dammers	D688,571 S	8/2013	Logue
	D372,867 S	8/1996 Lambelet, Jr.	8,499,531 B2	8/2013	Benetti et al.
	D382,474 S	8/1997 Malmberg	D689,373 S	9/2013	Logue
	5,740,717 A	4/1998 Sowden et al.	D689,374 S	9/2013	Logue
	D404,641 S	1/1999 Kelsey et al.	D689,778 S	9/2013	Logue
	D411,445 S	6/1999 Anderson	D691,465 S	10/2013	O'Brien et al.
	D414,106 S	9/1999 Anderson	D691,856 S	10/2013	Dabney-Wiggs
	D414,409 S	9/1999 Sanfilippo et al.	8,544,650 B2	10/2013	Williams-Hartman
	6,082,544 A *	7/2000 Romick B65D 83/0463 206/531	8,550,248 B1	10/2013	Busen
	6,138,830 A	10/2000 Muggli	8,556,077 B1	10/2013	Hanley
	D434,558 S	12/2000 Brady et al.	8,561,798 B2	10/2013	Hession
	6,273,260 B1	8/2001 Coldepietro et al.	8,567,606 B2	10/2013	Bellamah et al.
	D448,048 S	9/2001 Brown, III	8,573,403 B2	11/2013	Stevens et al.
	D457,246 S	5/2002 Mazel et al.	8,579,106 B2	11/2013	Naik et al.
	6,443,307 B1	9/2002 Burrige	8,584,857 B2	11/2013	Ozawa et al.
	6,516,949 B2	2/2003 Fuller et al.	D694,904 S	12/2013	Banes et al.
	6,622,856 B2	9/2003 Gallo et al.	8,602,218 B2	12/2013	Grosskopf
	D480,958 S	10/2003 Mazel et al.	8,607,982 B2	12/2013	Jones
	6,659,280 B2	12/2003 Paliotta et al.	8,607,983 B2	12/2013	Niven et al.
	6,679,382 B1	1/2004 Kancsar et al.	D697,095 S	1/2014	Chan
	6,793,077 B1	9/2004 Kancsar et al.	8,627,957 B2	1/2014	Ziemba et al.
	6,896,139 B2	5/2005 Kancsar et al.	8,640,917 B2	2/2014	Kracke
	6,997,320 B1	2/2006 Kancsar et al.	8,672,134 B2	3/2014	Sprada et al.
	D518,737 S	4/2006 Zalzal	8,740,003 B2	6/2014	Elliott
	7,063,211 B2	6/2006 Williams-Hartman	8,746,454 B2	6/2014	Doucet et al.
	D525,777 S	8/2006 Priebe et al.	8,752,704 B2	6/2014	Leon Alonso et al.
	D526,478 S	8/2006 Priebe et al.	8,757,381 B2 *	6/2014	Bouthiette B65D 1/34 206/528
	7,126,879 B2	10/2006 Snyder	D708,760 S	7/2014	Smeja
	7,188,728 B2	3/2007 Williams-Hartman	D708,761 S	7/2014	Smeja
	D546,198 S	7/2007 Currie et al.	D708,762 S	7/2014	Smeja
	D558,603 S	1/2008 Priebe et al.	D711,219 S	8/2014	Palsson
	7,360,652 B2	4/2008 Arnold	D713,051 S	9/2014	Smeja
	D574,665 S	8/2008 James	D723,279 S	3/2015	Wax
			2003/0034271 A1	2/2003	Burrige
			2003/0042167 A1 *	3/2003	Balz B65D 83/0463 206/531
			2003/0164380 A1	9/2003	Taneja et al.
			2006/0163110 A1 *	7/2006	Adler B65D 1/0223 206/534

(56)

References Cited

U.S. PATENT DOCUMENTS

2007/0185615	A1	8/2007	Bossi et al.	
2009/0038982	A1	2/2009	Doucet et al.	
2009/0242451	A1	10/2009	Kessler	
2009/0301924	A1 *	12/2009	Rondeau	B65D 83/0463 206/531
2011/0215022	A1	9/2011	Sack et al.	
2012/0248005	A1	10/2012	Bergey	
2012/0261275	A1 *	10/2012	Intini	A61J 1/035 206/532
2013/0008825	A1	1/2013	McArthur et al.	
2013/0193029	A1	8/2013	Weston et al.	
2013/0220870	A1	8/2013	Grosskopf	
2013/0220871	A1	8/2013	Bradford	
2013/0233756	A1	9/2013	Weston et al.	
2013/0256183	A1	10/2013	Ingraham	
2013/0281960	A1	10/2013	Hanley	
2013/0306511	A1	11/2013	Branyon et al.	
2014/0001194	A1	1/2014	Pipes et al.	
2014/0027340	A1	1/2014	Hession	
2014/0027341	A1	1/2014	Ludwig et al.	
2014/0083900	A1	3/2014	Ziemba et al.	
2014/0171436	A1	6/2014	Kamen et al.	
2014/0183095	A1	7/2014	Choubey et al.	
2014/0209498	A1	7/2014	Stevens	
2014/0214438	A1	7/2014	Ahmadi	
2014/0216968	A1	8/2014	Wagner et al.	
2014/0216977	A1	8/2014	Bowers et al.	

FOREIGN PATENT DOCUMENTS

AU	346153	S	1/2013
AU	348282	S	5/2013
AU	357121	S	8/2014
AU	359486	S	12/2014
CA	114356		3/2008
CA	120646		3/2014
CL	36012012		12/2012
CL	8902013		4/2013
CL	8912013		4/2013
EP	1211191		5/2002
EP	1481914	A1	12/2004
WO	2005120984		12/2005
WO	2010015638		2/2010
WO	2014057967		4/2014
WO	2014085625		6/2014

OTHER PUBLICATIONS

Japanese Office action for Design Application No. 2014-7623 dated Apr. 22, 2014. (1 page).
 International Search Report and Written Opinion for Application No. PCT/US2014/045459, mailed on Nov. 3, 2014, 18 pages.
 U.S. Appl. No. 29/424,276, filed Jun. 10, 2012, Akana et al.
 Chilean Patent Office Action for Application No. 2014-000864 dated Sep. 21, 2015 (8 pages).
 Chilean Patent Office Action for Application No. 2014-000866 dated Sep. 21, 2015 (8 pages).
 Chilean Patent Office Action for Application No. 2014-002839 dated Sep. 28, 2015 (6 pages).

* cited by examiner




FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3




FIG. 4




FIG. 5




FIG. 7






FIG. 6






FIG. 10









FIG. 11













ॐ
ॐ
ॐ














FIG. 23






FIG. 24






FIG. 27A




FIG. 27B




FIG. 27C




FIG. 28A




FIG. 28B




FIG. 29A




FIG. 29B




FIG. 30A




FIG. 30B




FIG. 31A




FIG. 31B




FIG. 32




FIG. 33





FIG. 34



55
56
57
58
59
60




FIG. 36A




FIG. 36B




FIG. 37a




FIG. 37b




FIG. 38




FIG. 39




FIG. 40

400




FIG. 41A




FIG. 41B





FIG. 41C



1

MEDICINE CONTAINER, METHOD OF ASSEMBLING THE CONTAINER, AND METHOD OF DISPENSING THE MEDICINE FROM THE CONTAINER

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a non-provisional of and claims the benefit of U.S. Provisional Patent Application No. 61/842,841, filed on Jul. 3, 2013, and U.S. Provisional Patent Application No. 61/842,900, filed on Jul. 3, 2013. This application also is a continuation of U.S. Patent Application No. 29/488,207, filed on Apr. 16, 2014, Pat. No. D731783. The entire contents of each application are fully incorporated herein by reference.

BACKGROUND OF THE INVENTION

Prescription medicines require a prescription prepared by a person authorized to prescribe medicine. A prescription medicine is dispensed by a pharmacist, and the prescription medicine typically comes with an information leaflet providing information about the medicine, its side effects, if any, instructions for use of the medicine, and any relevant cautions and warnings.

Most prescription medicines are dispensed by a pharmacist in a bottle or in a blister pack. Some prescription medicines that are dispensed in this manner have complicated instructions for use and may not be easy for a patient to remember. For example, some prescription medicines are to be taken in the morning, afternoon, or evening, some with or without food, some with or without certain types of food, and particular quantities. In these situations, a patient may need to read the bottle or refer back to the information leaflet for instructions when taking the medicine. A patient also may need to keep a log of when he or she took the medicine to ensure compliance with any timing instructions.

SUMMARY OF THE INVENTION

The present invention relates to a system and a container for securing and dispensing medicine that provides instructions for use that are visible upon access to and administration of the medicine. In particular, the invention relates to a container, which secures medicine and is child-resistant thereby preventing children from accessing the medicine enclosed within the container. The invention also relates to a method for assembling the child-resistant container. The invention also relates to a method for accessing or dispensing, by an intended user, the medicine secured within the child-resistant container.

Medication packaging is regulated by the government in an effort to ensure that the packaging is substantially child-resistant. Each medication package is constructed to meet specific criteria that are based on the contents within the package and the type and potency of the medication.

In one embodiment, the invention provides a child-resistant medication container assembly. The assembly comprises a blister pack including a plurality of compartments, each of the plurality of compartments configured to support at least one medication; a puck including a recess having a plurality of openings with each opening in the puck corresponding to one of the plurality of compartments of the blister pack; and a box including a first wall opposite a second wall, a plurality of openings extending through the first wall, each of the openings in the first wall being aligned with corresponding

2

perforations in the second wall, each of the openings in the first wall being aligned with one of the openings in the puck and a corresponding compartment of the blister pack.

In another embodiment the invention provides a method of assembling a child-resistant medication container. The method comprises aligning a blister pack including a plurality of compartments with a puck including a recess and a plurality of openings, each of the plurality of openings configured to be complementary to one of the plurality of compartments; attaching the blister pack to the puck; inserting the blister pack and the puck into a box, the box including a first wall opposite a second wall, a plurality of openings extending through the first wall and being aligned with a plurality of perforations in the second wall, each of the aligned plurality of openings and perforations being complementary to one of the plurality of compartments; and closing the box to enclose the blister pack and the puck.

In another embodiment the invention provides a method of dispensing medication secured within a child-resistant medication container to a user. The method comprises providing a container including a box, a puck, and a blister pack, the puck being secured to the box, and the blister pack being secured to the puck; applying a force to at least one compartment of a plurality of compartments of the blister pack, each of the plurality of compartments being aligned with a complementary one of a plurality of openings in a first wall of the box; breaking a seal of the at least one compartment to move medication contained within the at least one compartment; expelling the medication through an opening in the recess of the puck, the opening being complementary to the at least one compartment; and expelling the medication through a perforation in a second wall of the box, the perforation being complementary to the at least one compartment.

Other aspects of the invention will become apparent by consideration of the detailed description and accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a front perspective view of a medicine container assembly according to one embodiment of the invention.

FIG. 2A illustrates a box of the medicine container illustrated in FIG. 1.

FIG. 2B illustrates a puck or a template of the medicine container illustrated in FIG. 1.

FIG. 2C illustrates a blister pack of the medicine container illustrated in FIG. 1.

FIG. 3 is a front perspective view of a medicine container assembly in a first configuration according to another embodiment of the invention.

FIG. 4 is a front perspective view of the container illustrated in FIG. 3 in a second configuration.

FIG. 5 is a front perspective view of an exemplary blister pack.

FIG. 6 illustrates engineering drawing specifications of the exemplary blister pack of FIG. 5.

FIGS. 7 and 8 are front perspective views of a blister pack having another configuration.

FIG. 9 is a bottom perspective view of the blister packs illustrated in FIGS. 7 and 8.

FIG. 10 illustrates engineering drawing specifications of the blister pack of FIGS. 7 and 8.

FIG. 11 is a front perspective view of a blister pack having another configuration.

FIG. 12 is a perspective view of an exemplary puck.

FIG. 13 is a top view of the puck illustrated in FIG. 12.

3

FIG. 14 is a bottom view of the puck illustrated in FIGS. 12-13.

FIG. 15 is a top perspective view of an exemplary puck.

FIG. 16 is a bottom perspective view of the puck in FIG. 15.

FIG. 17 is a bottom view of the puck illustrated in FIG. 15.

FIG. 18 is a top view of the puck illustrated in FIGS. 15-16.

FIG. 19 is a perspective view of an exemplary puck.

FIG. 20 is a bottom perspective view of the puck in FIG. 19.

FIG. 21 is a bottom view of the puck in FIG. 19.

FIG. 22 is a top view of the puck illustrated in FIG. 19.

FIG. 23 is a rear view of the puck illustrated in FIG. 19.

FIG. 24 is a front view of the puck illustrated in FIG. 19.

FIG. 25 is a left side view of the puck illustrated in FIG. 19.

FIG. 26 is a right side view of the puck illustrated in FIG. 19.

FIGS. 27A, 27B, 27C illustrate front perspective views of an exemplary puck.

FIG. 28A illustrates a front perspective view of an exemplary puck.

FIG. 28B illustrates a rear perspective view of the puck illustrated in FIG. 28A.

FIG. 29A illustrates a front perspective view of an exemplary puck.

FIG. 29B illustrates a rear perspective view of the puck illustrated in FIG. 29A.

FIG. 30A illustrates a front perspective view of an exemplary puck.

FIG. 30B illustrates a rear perspective view of the puck illustrated in FIG. 30A.

FIG. 31A illustrates a front perspective view of an exemplary puck.

FIG. 31B illustrates a rear perspective view of the puck illustrated in FIG. 31A.

FIG. 32 illustrates an exemplary box blank.

FIG. 33 is an assembly view of the medicine container assembly illustrated in FIGS. 3-4 including the blister pack of FIGS. 5-6, the puck of FIGS. 19-26, and a box.

FIG. 34 is a perspective view of the blister pack and puck illustrated in FIG. 33 when assembled.

FIG. 35 illustrates a method for assembling the medicine container assembly of FIG. 33.

FIGS. 36A, 36B illustrate a method of use of the medicine container assembly of FIG. 33.

FIGS. 37A, 37B illustrate exemplary user instructions indicating the method of use of the medicine container assembly of FIGS. 36A, 36B.

FIG. 38 is a front perspective view of a dispenser of a medicine container assembly.

FIG. 39 is a front perspective view of a dispenser having another configuration.

FIG. 40 is a front view of the dispenser illustrated in FIG. 39.

FIG. 41A is a front perspective view of a dispenser of a medicine container assembly illustrated in FIGS. 3-4.

FIG. 41B is a front perspective view of the dispenser illustrated in FIG. 41A in an unopened configuration.

FIG. 41C is a front perspective view of the medicine container assembly illustrated in FIGS. 3-4.

FIG. 42 is an exemplary box blank of the dispenser.

DETAILED DESCRIPTION

Before any embodiments of the invention are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or

4

illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.

FIGS. 1 and 2A-C illustrate a container assembly or package 10 for medication according to a first embodiment of the invention. The medication may be acquired by prescription or available over-the-counter. The container assembly 10 includes a blister pack 20, a puck 100, and a box 150.

As illustrated in FIGS. 5-11, the blister pack or card 20 includes a first side 24, a second side 26, and outer walls 28 that define a perimeter of the blister pack 20. The blister pack 20 is constructed from a semi-rigid plastic film or member 32 having a foil and/or paper layer 36 adhered to the second side 26 thereof. The blister pack 20 includes a plurality of compartments or pockets 40 formed within the member 32 and sized and shaped to receive a pill-form of a medication 42 therein. The compartments 40 are defined by the semi-rigid plastic film and protrude from the first side 24 of the blister pack 20. As such, the compartments 40 define a height of the blister pack 20. The compartments 40 also define an opening 48 on the second side 26 of the blister pack 20 prior to adhering the film layer 36 in order to insert the at least one medication 42 therein. As illustrated in FIGS. 5 and 6, one or more of the compartments 40 may be empty when sealed thereby defining one or more air pockets or supporting knobs 50 in the blister pack 20. The foil layer 36 overlays the openings 48 when adhered to the second side 26 of the blister pack 20 thereby creating a seal 54 for securing the doses of medication 42 or the air pockets 48 in the appropriate compartment 40. The medication 42 secured in each of the plurality of compartments 40 is accessible by applying pressure to the desired compartment on the first side 24 of the blister pack 20 and thereby puncturing the seal 54 of the compartment 40. The medication is released through the opening 48 of the second side 26.

The seals 54 are created by a vacuum in order to enclose the medication 42 within the compartments 40. In the illustrated embodiments, the seals 54 and the compartments 40 enclose the medications 42 such that each of the doses of medication 40 is surrounded and protected by a surrounding air pocket. The air pocket protects the integrity of the dose of medication 40 (e.g., protects the medication from being crushed or prematurely expiring). The foil layer 36 includes one or more perforations or indentations to provide a point where an intended user may push the dose of medication 40 through the foil layer 36 in order to free the medication from the blister pack 20. Alternative or additional embodiments may include blister packs constructed from any suitable material(s) (e.g., cardboard, foam, etc.). Similarly, the compartments may be sealed using suitable alternative methods or materials.

As illustrated in FIGS. 5-11, the blister pack 20 may have a variety of suitable configurations, such as for example blister packs 20, 20a, 20b. The compartments 40 of the blister packs 20, 20a, 20b have a variety of sizes and shapes in order to accommodate different types, sizes, and doses of medications 40. For example, the compartments 40 may be circular, ovalar, cuboidal, rectangular, and the like. Similarly, the blister pack may include compartments including any suitable combination of shapes and sizes. In other words, because a dose of medication in the form of a pill or capsule may have many sizes and shapes, the blister pack can be manufactured to accommodate the specific size and shape of one or more types of medications. Further, many medications are adapted to be taken multiple times a day, at specific times of the day, and/or in combination with other medications. Therefore, each of the compartments may be sized and shaped to receive different types of medications and in any suitable orientation

5

to specify an order or series of administration. The second side 26 of the blister pack, and specifically the foil layer(s), may have many different configurations of perforations 58. For example, the perforations 58b may be located at each compartment 40. Alternatively, the perforations 58a may be configured so that only certain compartments 40 are punctured at a time, which will be discussed in greater detail below. The perforations 58 may also aid the user in administering the correct medications at the correct times. Furthermore, the air pockets or support knobs 50 may have alternative positions and configurations. For example, support knobs may be elongated air pockets or ribs 50. The ribs may extend along one or more sides of the blister pack, for example, or may be oriented in other ways relative to one or more of the compartments containing medication. Additionally, support knobs and support ribs may be used together in some embodiments.

FIGS. 5-11 also illustrate that the blister pack 20, 20a, 20b may be divided into regions or sections 60. For example, in FIGS. 5 and 6, the blister pack 20 is divided into a first region 60, a second region 60', and a third region 60". Each of the first, second, and third regions 60, 60', 60" include at least one of the compartments 40 of the blister pack 20. In the embodiment illustrated in FIGS. 5 and 6, the regions 60, 60', 60" may be separated from one another at a perforated edge or otherwise weakened lines 64 when they are used. In other words, the first region 60 may be torn away from the second and third regions 60', 60". As such, the user may remove the medication (s) within a particular region that may correspond to a certain dosage, combination or time period. The advantage of such a blister pack 20 is that specific medications can be removed from the corresponding compartments 40 without unintentionally puncturing the seals 54 of other, adjacent compartments. Regions of the blister pack may also be delineated by perforations in the second side of the blister pack. For example, FIGS. 7-10 include first and second perforations 58a. The perforations 58a are configured to provide easy access to the medications of the first region 60a while preserving the integrity of the seals 54a securing the medications of the second region 60a'. In addition to being physically delineated, regions of the blister packs 20 may be color-coded or provided with some other type of indicia to indicate and obviate the difference in the types of medication contained within each region or group of medications.

As noted above with respect to FIGS. 1 and 2A-C, the container assembly 10 includes the puck or template 100. The puck 100 is configured to be complementary to the compartments 40 of the blister pack 20. The puck 100 is a protective device or spacer component that provides a buffer between the blister pack 20 and the box 150. More particularly, the puck 100 provides rigidity to the finished box, deterring children from bending and breaking the perforations on the box around the medication while providing bite protection for the blister pack 20.

FIGS. 12-26 illustrate three different pucks 100. FIGS. 12-14 illustrate a first embodiment of the puck 100. The puck 100 includes a body portion 104 having a first side 102 spaced apart and opposite a second side 106. The body 104 also includes walls 108 extending between the first and second sides. The walls 108 define a height of the puck 100. The puck 100 also includes a recess 112 in the body 104. The puck 100 includes a plurality of openings 116 formed within the recess 112. Each of the plurality of openings 116 in the puck 100 is complementary to one of the compartments 40 of the blister pack 20, described above. As such, the openings 116 in the puck 100 are configured to align with the compartments 40 on the blister pack 20 having a specific orientation. For example,

6

the puck 100 of FIGS. 12-14 is specifically configured to accommodate the blister pack 20 illustrated in FIGS. 5 and 6. The blister pack 20 is coupled to the second side 106 of the puck 100 such that each of the compartments 40 is inserted through the respective complementary opening 116 in the puck 100. In some constructions, the blister pack 20 is applied (e.g., glued, sealed, taped, etc.) to the second side 106 of the puck 100 (this is shown in FIG. 35 as well).

With continued reference to FIGS. 12-14, the second side 106 of the body 104 includes a plurality of reinforced cavities 120 extending between the walls 108 and the recess 112. In other embodiments, the second side 106 may be solid. Additionally, FIGS. 13 and 14 include walls 108 that each have substantially the same thickness. However, alternate or additional embodiments may include walls having different thicknesses. The puck 100 can comprise paper pulp or other paper based substrates, however other materials, such as, plastic, or other suitable materials or combinations of materials may also be utilized in puck 100.

FIGS. 15-18 illustrate a second embodiment of the puck (referred to as puck 100a). The puck 100a includes a body portion 104a having a first side 102a spaced apart and opposite a second side 106a. The body 104a also includes walls 108a extending between the first and second sides. The walls 108a, 108a' define a height of the puck 100a. The puck 100a also includes a recess 112a in the body 104a. The puck 100a includes a plurality of openings 116a formed within the recess 112a. Each of the plurality of openings 116a in the puck 100a is complementary to one of the compartments 40 of the blister pack 20, described above. As such, the openings 116a in the puck 100a are configured to align with the compartments 40 on the blister pack 20 having a specific orientation. For example, the puck 100a of FIGS. 15-18 is specifically configured to accommodate the blister pack 20 illustrated in FIGS. 5 and 6. The blister pack 20 is coupled to the second side 106a of the puck 100a such that each of the compartments 40 is inserted through the respective complementary opening 116a in the puck 100a. In some constructions, the blister pack 20 is applied (e.g., glued, sealed, taped, etc.) to the second side 106a of the puck 100a (this is shown in FIG. 35 as well).

With continued reference to FIGS. 15-18, the walls 108a and 108a' have varying thicknesses. For example, the thickness of the wall 108a is different than the thickness of the wall 108a'. As illustrated, the thickness of the wall 108a is less than the thickness of the wall 108a'. The walls 108a' also includes a plurality of apertures 124a. The apertures 124a are cylindrical, and while eleven cylindrical apertures are illustrated, there may be fewer or more cylindrical apertures in other constructions. The walls 108a, 108a' form a raised rim 128a around a perimeter of the bottom wall (see FIGS. 16-17). The walls 108a angle inwardly at one end of the puck 100a. The angled portion of the wall 108a allows for easier insertion of the puck 100a into the box 150. The puck 100a can comprise plastic and be manufactured using an injection molding process, however, other suitable materials or combinations of materials may also be utilized for the puck 100a.

FIGS. 19-26 illustrate a third embodiment of the puck (referred to as puck 100b). The puck 100b includes a body portion 104b having a first side 102b spaced apart and opposite a second side 106b. The body 104b also includes walls 108b extending between the first and second sides. The walls 108b, 108b' define a height of the puck 100b. The puck 100b also includes a recess 112b in the body 104b. The puck 100b includes a plurality of openings 116b formed within the recess 112b. Each of the plurality of openings 116b in the puck 100b is complementary to one of the compartments 40

7

of the blister pack 20, described above. As such, the openings 116b in the puck 100b are configured to align with the compartments 40 on the blister pack 20 having a specific orientation. For example, the puck 100b of FIGS. 19-26 is specifically configured to accommodate the blister pack 20 illustrated in FIGS. 5 and 6. The blister pack 20 is coupled to the second side 106b of the puck 100b such that each of the compartments 40 is inserted through the respective complementary opening 116b in the puck 100b. In some constructions, the blister pack 20 is applied (e.g., glued, sealed, taped, etc.) to the second side 106a of the puck 100b (this is shown in FIG. 35 as well).

With continued reference to FIGS. 19-26, the walls 108b and 108b' have varying thicknesses. For example, the thickness of the wall 108b is different than the thickness of the wall 108b'. As illustrated, the thickness of the wall 108b is less than the thickness of the wall 108b'. The walls 108b' also includes a plurality of apertures 124b. The apertures 124b are rectangular, and while three rectangular apertures are illustrated, there may be fewer or more rectangular apertures in other constructions. The walls 108b, 108b' form a raised rim 128b around a perimeter of the bottom wall (see FIGS. 20-21). The walls 108b angle inwardly at one end of the puck 100b. The angled portion of the wall 108b allows for easier insertion of the puck 100b into the box 150.

The walls 108b, 108b' include a ribbed surface 130b at the outer ends of the walls. The ribbed surface 130b provides a larger surface area for application of glue or other bonding material(s) for securing the puck 100b to the box 150. The puck 100b can comprise plastic, and be manufactured using an injection molding process, however, other suitable materials or combinations of materials may also be utilized for the puck 100b.

FIGS. 27A-C illustrate a fourth embodiment of the puck (referred to as puck 100c). The puck 100c includes a first portion 504 and a second portion 508 that are configured to couple together as illustrated. For example, the first portion 504 has a bottom wall 512 and a side wall 516 that extends around a perimeter of the bottom wall 512 thereby defining a recess 520. The second portion 508 includes a top wall 524 having a defined perimeter and a side wall 528 that extends from the top wall 524 at a position inset from the perimeter. The top wall 524 includes an overhang that extends over or beyond the side wall 528 and that rests on the top of the side wall 516. This configuration allows the side wall 528 of the second portion 508 to slide or fit within the recess 520 of the first portion 504.

The first portion includes a plurality of openings 532 positioned within the bottom wall 512. The second portion includes a plurality of openings 532' positioned within the top wall 524 and substantially aligned with the openings 532. An area 536 around each of the plurality of openings 532' is scalloped where a portion of the top wall 524 is gradually removed with less material being removed as the area transitions from the opening 532' and moving outwardly. The blister pack 20a is positioned between the first portion 504 and the second portion 508 and the compartments aligned with the openings 532, 532' before inserting the puck 100c into the box 150.

FIGS. 28A-B illustrate a fifth embodiment of the puck (referred to as puck 100d). The puck 100d includes a base 540 having a top surface 544 and a bottom surface 548 thereby defining a thickness therebetween. The base 540 includes a sidewall 552 extending between the top surface 544 and the bottom surface 548 and defining a perimeter. The side wall 552 may be angled at an end of the base 540. The base 540 includes a plurality of openings 556. The top surface 544

8

includes an area 560 around all of the openings 556 that is scalloped where a portion of the top surface 544 is gradually removed with less material being removed as the area transitions from the opening 556 and moving outwardly.

The puck 100d includes a plurality of individual compartments 562 formed by a first layer of material 564 and a second layer of material 566. The individual compartments 562 support the medication, and the first and second layers of material are secured to the base 540. After the medication and compartments 562 are secured to the base 540, the puck 100d is inserted into the box 150.

FIGS. 29A-B illustrate a sixth embodiment of the puck (referred to as puck 100e). The puck 100e includes a bottom wall 570 and a side wall 574 extending around the bottom wall 570. The side wall 574 can include varying thicknesses. As illustrated the two end walls (the shorter walls) have a greater thickness than the front and back walls (the longer walls). As illustrated, the side wall is angled at an end of the puck 100e. The bottom wall 570 includes a first portion 578 having a first thickness and a second portion 580 having a second thickness. As illustrated, the second portion 580 has a greater thickness than the first portion 578, however the first portion 578 in other constructions can have a greater thickness. The bottom wall 570 includes a plurality of openings 584. The blister pack 20 is coupled to the puck 100e with the compartments aligned with the openings 584 before inserting the puck 100e into the box 150.

FIGS. 30A-B illustrate a seventh embodiment of the puck (referred to as puck 100f). The puck 100f is similar to the puck 100 described above. The puck 100f includes a plurality of recesses 588 formed at various locations around a perimeter of the puck 100f.

FIGS. 31A-B illustrate an eighth embodiment of the puck (referred to as puck 100g). The puck 100g includes a base 590 having a top surface 594 and a bottom surface 598 thereby defining a thickness therebetween. The base 590 includes a sidewall 602 extending between the top surface 594 and the bottom surface 598 and defining a perimeter. The side wall 602 may be angled at an end of the base 590. The base 590 includes a plurality of openings 604. The top surface 594 includes an area 608 around some of the openings 604 that is scalloped where a portion of the top surface 594 is gradually removed with less material being removed as the area transitions from the opening 604 and moving outwardly. The bottom surface 598 includes a recessed area 610 around all of the openings 604. The blister pack 20 is coupled to the puck 100g with the compartments aligned with the openings 604 before inserting the puck 100g into the box 150.

The pucks 100, 100a-g of FIGS. 12-18 and 27-31 may also include ribbed surfaces as described above. Additionally, the ribbed surfaces may be included on additional or alternative surfaces and sides of the pucks 100, 100a-g. Further, although only illustrated in puck 100b, there may be a recess or other indicia 131b (e.g., orientation arrow) that indicates an orientation for which the puck 100b should be loaded when assembling the medicine container 10.

The pucks 100, 100a-g illustrated and described herein are merely exemplary. Pucks having additional configurations and features are within the scope and spirit of the invention. Therefore, it should be understood that the configuration of the plurality of openings may be adapted to any unique configuration of blister pack. Additionally, body portion, walls, and recess may have any suitable shape or size or dimension. Furthermore, the illustrated pucks may be formed from a composite material including paper pulp and bamboo fiber. The pulp/fiber combination is advantageous because it is

environmentally safe and recyclable. However, other materials may be used to form the puck.

As noted above with respect to FIGS. 1 and 2A-C, the medicine container assembly 10 includes the box 150. With reference to FIG. 32, the box 150 is constructed from a substrate such as, fiberboard, cardboard or the like. The substrate is processed and cut into a box blank as illustrated in FIG. 32. The box blank is manipulated and folded where noted to form the box 150.

With additional reference to FIGS. 1 and 3-4, the box 150 includes a plurality of walls that together define a cavity 154 therein. Specifically, the box 150 includes a first wall 158 spaced apart from and opposite a second wall 162. The first and second walls 158, 162 are spaced apart by intermediate walls 166. The first wall 158 includes a first side, which faces the cavity 154, and a second side, which faces an exterior of the box 150. The first wall 158 includes a plurality of openings 170 extending between the first and second sides and a protrusion 174 (FIG. 32) extending from the second side. The second wall 162 includes a first side, which faces the cavity 154, and a second side, which faces an exterior of the box 150. The second wall 158 includes a plurality of perforations 178.

FIGS. 33-37A,B illustrate a method of assembling the medication container assembly 10. In particular, the blister pack 20 and one of the pucks 100, 100a-g are configured to be received and secured within the box 150. The cavity 154 receives and secures the puck 100, 100a-g and blister pack 20 therein.

The following description is specific to pucks 100, 100a, 100b, however concepts are similar for pucks 100c-g where similar parts/components are noted but may have different numerals.

The blister pack 20 is coupled to the puck 100, 100a, 100b such that each of the plurality of compartments 40 is aligned with and protrudes through the corresponding plurality of openings 116 into the recess 112 of the puck 100. Glue may be applied to the blister pack to adhere the blister pack to the body 104, 104a, 104b of the puck 100, 100a, 100b. With the puck 100b, glue or other bonding material(s) is applied to the ribbed surfaces 130b at the ends of the walls 108b' to secure the puck 100b to the corresponding side walls of the box 150.

When secured within the cavity 154 of the box 150, the plurality of compartments 40 and plurality of openings 116, 116a, 116b in the puck 100, 100a, 100b are aligned with the plurality of openings 170 in the first wall 158 and plurality of perforations 178 in the second wall 162. As such, the medication 42 within the cavity 154 is viewable through the plurality of openings 170 in the first wall 158. Within the cavity 154, a gap (not shown) is created between the compartments 40 and the first wall 158 such that the compartments 40 are recessed relative to the first wall 158. Furthermore, the support knobs or ribs 50 of the blister pack 20 are not aligned with corresponding openings or perforations in the first and second walls. As such, the support knobs and ribs 50 maintain the gap or distance as medications 42 are expelled from the compartments 40 and the once medicine-filled compartments 40 are no longer able to retain their shape. A force applied through the plurality of openings 170 in the first wall to one or more of the compartments 40 causes the medication 42 to puncture the seal 54 in the blister pack 20 and severs the perforations 178 from the second wall 162. As such, the medication contained within one or more of the compartments 40 is expelled through the respective opening 116 in the puck 100 thereby creating holes in the second wall 162 of the box (FIGS. 36A-B). Instructions for use 300 and medication information 304 may be included on an instruction card 308 included in the packaging (FIGS. 37A-B).

A third wall or overlay 182 is hingedly coupled to the first wall 158 and/or one of the intermediate walls 166. The third wall 182 includes a first side, which includes medication information, and a second side. The first side of the third wall 182 includes an opening or recessed portion 186 that includes an adhesive configured to couple or removably adhered to the first wall 158. The third wall 182 includes a securement tab or seal 190 (FIGS. 4, 38). In a first closed position (FIGS. 4, 38), the securement tab 190 is secured to one of the intermediate walls 166 such that the cavity 154, and therefore the medication 42 contained within the blister pack 20 is inaccessible. In a second, open position, the securement tab 190 is released from the intermediate wall 166 thereby allowing the third wall 182 to pivot relative to the first wall 158. Once the securement tab 190 has been released, the cavity 154, and therefore the medication contained within the blister pack 20 is accessible. After the securement tab 190 has been released and medication 42 is dispensed, the opening 186 in the third wall 182, which includes an adhesive, may be removably adhered to the first side 158 to temporarily prevent access to the cavity 154 and medication 42 therein.

The box 150 may also include printed portions that provide instructions for administration of the medication contained therein. For example, in the embodiments illustrated and described herein, the box 150 may include regions or sections 194, 194' that correspond to regions in the blister pack 20. As such, a first region 194 of the box 150 may correspond to a first region (i.e., the first and second regions 60, 60' in FIGS. 5 and 6) while a second region 194' of the box 150 may correspond to a second region (i.e., the third region 60" in FIGS. 5 and 6) of the blister pack 20. The first region 194 of the box 150 is printed with corresponding instructions related to the medication in the first region. For example, the first region 194 includes instructions on when to take the medication and under what conditions the medication should be administered. Similarly, the second region 194' of the box 150 is printed with corresponding instructions related to the medication in the second region. For example, the second region 194' includes instructions on when to take the medication and under what conditions the medication should be administered. The instructions may also include a color code to more clearly delineate how the medication contained with the container is to be administered. For example, the first region 194 of the box 150 includes a first color (i.e., associated with morning or day time) while the second region 194' of the box 150 includes a second color (i.e., associated with evening or night time).

The medicine container assembly 10 includes several features that prevent a child from accessing the medication contained therein. First, at least the first wall 158 preferably includes a film overlay or laminate, which makes it more difficult for a child to tear or rip the container 10 at or near the openings 170. Additionally, the walls include a glue or other suitable adhesive that effectively couples the walls together, thus preventing a child from easily accessing the interior contents of the container 10. Further, the securement tab 190 is preferably a tamper-evident indicator tab. That is, releasing the securement tab 190 from the intermediate wall changes 166 the color (i.e., by removing a layer of paint or material or the like) of first and second indicator tabs 200. The color of the indicator tabs 200, which is different from the color of the surrounding wall 166, indicates to the user that the securement tab 190 has been initially removed. The securement tab 190 and indicator tabs 200 are advantageous because they alert the user that someone else has already tried to access the medication secured within the container 10. This feature is particularly advantageous to alert parents that a child may

11

have had access to the medication. Another child-resistant feature of the container 10 is that once the third wall 182 has been released by the securement tab 190 and the cavity 154 and medication are accessible, the gap between the first wall 158 and plurality of compartments 40 increase the distance and force necessary to break the seal 54 in the blister pack 20 and sever the perforations 178. The force necessary to dispense the medication is further increased by the puck 100, which introduces added stiffness and rigidity to the assembled container 10. The medication container 10 is thus constructed to prevent children from accessing the medication secured therein and to meet regulatory standards for child-resistant packaging.

The medicine container 10 is assembled using one or more of the following steps. First, the box 150 is prepared and folded. As illustrated in FIG. 32, prior to being assembled, the box blank includes a first side and a second side. The box blank further includes a first section 250, a second section 254 and a third section 258, which are arranged linearly. The first section 250 includes first, second, and third projections 260a-260c, the second section 254 includes fourth and fifth projections 262a, 262b, and the third section 258 includes the securement tab 190 and a label portion 270 coupled thereto. A first intermediate section 280 is disposed between the first and second sections 250, 254 and a second intermediate section 284 is disposed between the second and third sections 254, 258. The first intermediate section 280 includes the indicator tabs 200. The first section 250 includes the plurality of openings 170 extending between the first and second sides, indicated by the solid lines, while the second section 254 includes the plurality of perforations 178, indicated by the dashed lines.

The box blank is assembled by bending the first section 250 along a point of connection between the first section 250 and the first intermediate section 280. Similarly, the second section 254 is bent along a point of connection between the first intermediate section 280 and the second section 254. In doing so, the first section 250, which forms the first wall 158, is spaced apart from the second section 254, which forms the second wall 162, by the first intermediate section 280, which is one of the intermediate walls 166. The third projection 260c extending from the first section 250 is then secured (i.e., by adhesive or the like) to the second intermediate section 284. The first and second intermediate sections 280, 284 are therefore two of the intermediate walls 166 between the first and second walls 158, 162 of the box blank. When coupled by the intermediate walls 166, the first and second walls 158, 162 are parallel to one another such that the plurality of openings 170 in the first wall 158 are aligned with the plurality of perforations 178 in the second wall 162. The plurality of openings 170 are also complementary to the plurality of perforations 178. The first and second walls 158, 162 also define a portion of the cavity 154 when coupled by two of the four intermediate walls 166.

Prior to being inserted in the cavity 154, the blister pack 20 is applied to the puck such that each of the plurality of compartments of the blister pack 20 is aligned with the plurality of openings 116 in the puck 100. As discussed above, each of the plurality of openings 116 is configured to be complementary to one of the plurality of compartments. Then, together, the blister pack 20 and puck 100 are inserted into the box 150 between the first and second walls 158, 162. The plurality of openings 170 extending through the first wall 158 of the box 150 are aligned with the plurality of perforations 178 in the second wall 162. Each of the plurality of openings 116 of the puck 100 align with the plurality of openings 170 in the first wall 158 and plurality of perforations 178 in the second wall

12

162. Furthermore, like the openings 116 in the puck 100, each of the aligned plurality of openings 170 in the first wall 158 and plurality of perforations 176 in the second wall 162 are complementary to and aligned with one of the plurality of compartments 40. As such, the medication 42 within the cavity 154 is viewable through the plurality of openings 170 in the first wall 158.

The medicine container assembly 10 is assembled by securing the blister pack 20 and puck 100 within the cavity 154 of the box 150 such that the medication in each of the plurality of compartments 40 is viewable through the plurality of openings 170 in the first wall 158. Accordingly, auxiliary tabs 304 extending from each of the first and second intermediate sections 280, 284 and the first and second projections 260a, 262a, 260b, 262b extending from each of the first and second sections 250, 254 (e.g., first and second walls 158, 162) are folded. As such, the first projections 260, 262a overlap and are secured to the second projections 260b, 262b, which overlap and are secured to the auxiliary projections 304. The walls of the box blank are secured by glue or another suitable adhesive.

The medication information, which might include instructions, dosing information, or information about the medication, is coupled (e.g., by an adhesive) to the first side of the third wall 182. The third wall 182 is then such that the third wall 182 overlays the first wall 158. The securement tab 190 is then coupled to one of the intermediate walls 166 to complete the assembly of the container 10. In the embodiments illustrated in FIGS. 1-37A,B, the blister packs 20, 20a, 20b, the pucks 100, 100a-g, and the box 150 are configured to receive and secure a daily dose of medication. However, in additional or alternative embodiments, the blister packs, the pucks, and the box may be configured to receive and secure hourly, weekly, or monthly medication doses. For example, the box 150' of FIG. 42, when assembled, is configured to receive and secure a blister pack and puck that receive and secure a weekly dose of medication. As illustrated in FIG. 42, the concepts discussed herein are similar except that the aperture/perforation configuration accommodates a different number and size of medication/pill.

The medicine container assembly 10 may be used to dispense appropriate doses of medication secured therein according to one or more of the following steps. First, the securement tab 190 is released such that the third wall 182 moves from a first, closed position (FIGS. 4, 38, 41A-C) in which the third wall 182 overlays the first wall 158 to a second, open position (FIGS. 1, 3) in which the first wall 158 and the cavity 154 of the box 150 are accessible. Upon the release of the securement tab 190, the indicator tabs 166 turn to a color that is different than the color of the surrounding wall. In the open position, instructions for appropriate administration of the medication are clearly visible. One or more doses of medication contained in the respective one or more of the plurality of compartments 40 of the blister pack 20 is expelled by applying a substantial force through the corresponding complementary opening 170 in the first wall 158 to a surface of the compartment 40. The force causes the medication secured within the compartment 40 to puncture the seal 54 in the second side 26 of the blister pack 20 thereby moving the medication or pill through the opening 48 of the compartment 40. The force continues to move the medication through the corresponding complementary opening 116 in the puck 100 such that the force of the medication against the corresponding complementary perforation 178 causes the perforation 178 to sever from the surrounding second wall 162. Therefore, a hole in the second wall 162 is created as the medication is expelled from the container 10. Once the medi-

13

cation has been dispensed, the third wall **182** may be moved from the second, open position to a third resealed position (not shown). Once again, access to the cavity **154**, and therefore the medication contained therein, is inaccessible. Therefore, the plurality of openings **170** in both the first wall **158** of the box **150** and the puck **100** and the plurality of perforations **178** in the second wall **162** of the box **150** are all complementary and configured to be aligned.

As illustrated in FIGS. **38-39**, **41A-C** one or more of the child-resistant medicine container assemblies **10** may be housed in and dispensed from a gravity-feed dispenser **400**. The gravity-feed dispenser **400** has a first side, second side, front side, back side, a top side and a bottom side. The dispenser **400** further includes a substantially rectangular body **404** defined by six walls **408**, which enclose a substantially rectangular cavity **412**. An aperture or opening **416** sized and shaped to receive one child-resistant medication container **10** extends along a bottom of a front wall of the dispenser **400** and between a first side wall and a second, opposite side wall of the container **10**. The aperture **416** is spaced apart from a bottom wall by a gap or platform **420**, which includes a plurality of protrusions **424**. A non-removable lid **430** is coupled to the top side of the dispenser **400**. Once the one or more containers **10** are stacked within the cavity **412**, the lid **430** is irremovably sealed to the body **404** of the dispenser **400** such that the containers **10** cannot be removed through the top of the dispenser **400**. A bottom container **10a** is disposed within the aperture **416**, and the other containers **10a'** are stacked on top of the bottom container **10a** within the cavity **412**. The bottom container **10a** may be removed from the dispenser **400** by grasping the container **10a** through the openings created by the aperture **416** in the first and second side walls.

Once the bottom container **10a** is removed, an adjacent container **10a'**, and therefore all of the other containers **10a'** move downward. The adjacent container **10a'** becomes the bottom container **10a** and is disposed within the aperture **416** and is ready to be removed. Once a container **10a** is removed, one of the protrusions **424** may be depressed to indicate that container **10a** has been removed. For example, the dispenser in the illustrated embodiment is sized and shaped to house seven containers **10** (e.g., a one week's worth of the medication) and the gap includes seven protrusions, one for each day of the week. On a first day of the week (e.g., Monday), the first, bottom container **10** is removed and the first protrusion is depressed. Therefore, the user is alerted to the fact that there should be six containers remaining in the dispenser, which is evident by the through hole in at least one of the first and second side walls or the rear wall and by the six remaining un-depressed protrusions. The dispenser is considered a child-resistant feature because the intended user can modify the amount of containers that are housed in the dispenser compared to the amount of containers that should be in the dispenser.

Thus, the invention provides, among other things, a child-resistant medication container. The invention additionally provides a method of assembling the child-resistant medication container. The invention further provides a method of dispensing medication from a child-resistant medication container. The invention also provides a dispenser for dispensing a plurality of child-resistant medication containers.

Various features and advantages of the invention are set forth in the following claims.

What is claimed is:

1. A child-resistant medication container assembly comprising:

14

a blister pack including a plurality of compartments, each of the plurality of compartments configured to support at least one medication;

a puck including a recess having a plurality of openings with each opening in the puck corresponding to one of the plurality of compartments of the blister pack; and

a box including a first wall opposite a second wall, a plurality of openings extending through the first wall, each of the openings in the first wall being aligned with corresponding perforations in the second wall, each of the openings in the first wall being aligned with one of the openings in the puck and a corresponding compartment of the blister pack.

2. The child-resistant medication container of claim 1 wherein each of the plurality of compartments is spaced apart from the complementary opening in the box.

3. The child-resistant medication container of claim 1 wherein the box includes a series of instructions for administering the medication secured within the plurality of compartments of the blister pack.

4. The child resistant medication container of claim 1 wherein the blister pack further includes a first region and a second region, each of the first and second regions including at least one of the plurality of compartments.

5. The child resistant medication container of claim 4 wherein the box further includes a first region and a second region, each of the first and second regions including at least one of the plurality of openings.

6. The child resistant medication container of claim 5 wherein the first region of the blister pack is aligned with the first region of the box, and the second region of the blister pack is aligned with the second region of the box.

7. The child resistant medication container of claim 5 wherein the first region of the box includes a first set of instructions for administering the medication secured in the at least one of the plurality of compartments of the first region and wherein the second region of the box includes a second set of instructions for administering the medication secured in the at least one of the plurality of compartments of the second region.

8. The child resistant medication container of claim 1 wherein the box is constructed from cardboard having a layer of tear-resistant film.

9. The child resistant medication container of claim 1 wherein the puck further includes a plurality of openings extending through the recess, each of the plurality of openings configured to be complementary to and in alignment with one of the plurality of compartments.

10. The child resistant medication container of claim 1 wherein the puck includes a height that is greater than a height of one of the compartments of the blister pack.

11. The child resistant medication container of claim 1 wherein the puck is constructed from molded paper pulp and bamboo fiber.

12. The child resistant medication container of claim 1 wherein the medication secured in each of the plurality of compartments is accessible by puncturing a seal in the blister pack.

13. The child resistant medication container of claim 1 wherein the box is assembled and secured by glued-end construction.

14. The child resistant medication container of claim 1 wherein the box includes a third wall hingedly coupled to the first wall, the third wall overlaying the first wall to prevent access to the plurality of openings in the box.

15. A method of assembling a child-resistant medication container, the method comprising:

15

aligning a blister pack including a plurality of compartments with a puck including a recess and a plurality of openings, each of the plurality of openings configured to be complementary to one of the plurality of compartments;

attaching the blister pack to the puck;

inserting the blister pack and the puck into a box, the box including a first wall opposite a second wall, a plurality of openings extending through the first wall and being aligned with a plurality of perforations in the second wall, each of the aligned plurality of openings and perforations being complementary to one of the plurality of compartments; and

closing the box to enclose the blister pack and the puck.

16. The method of assembling a child-resistant medication container of claim **15** wherein inserting the blister pack and puck into the box includes maintaining a gap between the plurality of compartments and the plurality of openings in the first wall.

17. The method of assembling a child-resistant medication container of claim **15** wherein securing the blister pack and the puck within the box includes overlaying and securing a third wall over the first wall.

18. The method of assembling a child-resistant medication container of claim **15**, further comprising printing on the box a series of instructions for administering the medication secured within the plurality of compartments.

19. The method of assembling a child-resistant medication container of claim **15** further comprising:

providing the blister pack with a first region and a second region, each of the first and second regions including at least one of the plurality of compartments;

providing the box with a first region and a second region, each of the first and second regions including at least one of the plurality of openings;

16

aligning the first region of the blister pack with the first region of the box;

aligning the second region of the blister pack with the second region of the blister pack;

5 printing on the first region of the box a first instruction for administering the medication secured within the at least one of the plurality of compartments of the first region; and

10 printing on the second region of the box a second instruction for administering the medication secured within the at least one of the plurality of compartments of the second region.

20. A method of dispensing medication secured within a child-resistant medication container to a user, the method comprising:

providing a container including a box, a puck, and a blister pack, the puck being secured to the box, and the blister pack being secured to the puck;

20 applying a force to at least one compartment of a plurality of compartments of the blister pack, each of the plurality of compartments being aligned with a complementary one of a plurality of openings in a first wall of the box; breaking a seal of the at least one compartment to move medication contained within the at least one compartment;

expelling the medication through an opening in the recess of the puck, the opening being complementary to the at least one compartment; and

30 expelling the medication through a perforation in a second wall of the box, the perforation being complementary to the at least one compartment.

* * * * *

CLAIMS GRANTED IN EEUU

1. A child-resistant medication container assembly comprising:

a blister pack including a plurality of compartments, each of the plurality of compartments configured to support at least one medication;
a puck including a recess having a plurality of openings with each opening in the puck corresponding to one of the plurality of compartments of the blister pack; and
a box including a first wall opposite a second wall, a plurality of openings extending through the first wall, each of the openings in the first wall being aligned with corresponding perforations in the second wall, each of the openings in the first wall being aligned with one of the openings in the puck and a corresponding compartment of the blister pack.
2. The child-resistant medication container of claim 1 wherein each of the plurality of compartments is spaced apart from the complementary opening in the box.
3. The child-resistant medication container of claim 1 wherein the box includes a series of instructions for administering the medication secured within the plurality of compartments of the blister pack.
4. The child resistant medication container of claim 1 wherein the blister pack further includes a first region and a second region, each of the first and second regions including at least one of the plurality of compartments.
5. The child resistant medication container of claim 4 wherein the box further includes a first region and a second region, each of the first and second regions including at least one of the plurality of openings.
6. The child resistant medication container of claim 5 wherein the first region of the blister pack is aligned with the first region of the box, and the second region of the blister pack is aligned with the second region of the box.

7. The child resistant medication container of claim 5 wherein the first region of the box includes a first set of instructions for administering the medication secured in the at least one of the plurality of compartments of the first region and wherein the second region of the box includes a second set of instructions for administering the medication secured in the at least one of the plurality of compartments of the second region.
8. The child resistant medication container of claim 1 wherein the box is constructed from cardboard having a layer of tear-resistant film.
9. The child resistant medication container of claim 1 wherein the puck further includes a plurality of openings extending through the recess, each of the plurality of openings configured to be complementary to and in alignment with one of the plurality of compartments.
10. The child resistant medication container of claim 1 wherein the puck includes a height that is greater than a height of one of the compartments of the blister pack.
11. The child resistant medication container of claim 1 wherein the puck is constructed from molded paper pulp and bamboo fiber.
12. The child resistant medication container of claim 1 wherein the medication secured in each of the plurality of compartments is accessible by puncturing a seal in the blister pack.
13. The child resistant medication container of claim 1 wherein the box is assembled and secured by glued-end construction.
14. The child resistant medication container of claim 1 wherein the box includes a third wall hingedly coupled to the first wall, the third wall overlaying the first wall to prevent access to the plurality of openings in the box.

15. A method of assembling a child-resistant medication container, the method comprising:

aligning a blister pack including a plurality of compartments with a puck including a recess and a plurality of openings, each of the plurality of openings configured to be complementary to one of the plurality of compartments;

attaching the blister pack to the puck;

inserting the blister pack and the puck into a box, the box including a first wall opposite a second wall, a plurality of openings extending through the first wall and being aligned with a plurality of perforations in the second wall, each of the aligned plurality of openings and perforations being complementary to one of the plurality of compartments; and

closing the box to enclose the blister pack and the puck.

16. The method of assembling a child-resistant medication container of claim 15 wherein inserting the blister pack and puck into the box includes maintaining a gap between the plurality of compartments and the plurality of openings in the first wall.

17. The method of assembling a child-resistant medication container of claim 15 wherein securing the blister pack and the puck within the box includes overlaying and securing a third wall over the first wall.

18. The method of assembling a child-resistant medication container of claim 15, further comprising printing on the box a series of instructions for administering the medication secured within the plurality of compartments.

19. The method of assembling a child-resistant medication container of claim 15 further comprising:

providing the blister pack with a first region and a second region, each of the first and second regions including at least one of the plurality of compartments;

providing the box with a first region and a second region, each of the first and second regions including at least one of the plurality of openings;

aligning the first region of the blister pack with the first region of the box;

aligning the second region of the blister pack with the second region of the blister pack;

printing on the first region of the box a first instruction for administering the medication secured within the at least one of the plurality of compartments of the first region; and

printing on the second region of the box a second instruction for administering the medication secured within the at least one of the plurality of compartments of the second region.

20. A method of dispensing medication secured within a child-resistant medication container to a user, the method comprising:

providing a container including a box, a puck, and a blister pack, the puck being secured to the box, and the blister pack being secured to the puck;

applying a force to at least one compartment of a plurality of compartments of the blister pack, each of the plurality of compartments being aligned with a complementary one of a plurality of openings in a first wall of the box;

breaking a seal of the at least one compartment to move medication contained within the at least one compartment;

expelling the medication through an opening in the recess of the puck, the opening being complementary to the at least one compartment; and

expelling the medication through a perforation in a second wall of the box, the perforation being complementary to the at least one compartment.

TRADUCCIÓN REIVINDICACIONES OTORGADAS EN ESTADOS
UNIDOS

1. Un conjunto de envase de medicamento a prueba de niños, que comprende:

un envase blíster que incluye una pluralidad de compartimientos, configurado cada uno de la pluralidad de compartimientos para sostener al menos un medicamento;

una plancha que incluye un hueco que tiene una pluralidad de aberturas, correspondiendo cada abertura de la plancha a uno de la pluralidad de compartimientos del blíster ; y

una caja que incluye una primera pared opuesta a una segunda pared, una pluralidad de aberturas que se extienden a través de la primera pared, alineadas cada una de las aberturas de la primera pared con las correspondientes perforaciones de la segunda pared, alineadas cada una de las aberturas de la primera pared con una de las aberturas de la plancha y un correspondiente compartimiento del blíster .

2. El envase de medicamento a prueba de niños de la reivindicación 1, donde cada uno de la pluralidad de compartimientos está separado de la abertura complementaria de la caja.

3. El envase de medicamento a prueba de niños de la reivindicación 1, en donde la caja incluye una serie de instrucciones para administrar el medicamento asegurado dentro de la pluralidad de compartimientos del blíster.

4. El envase de medicamento a prueba de niños de la reivindicación 1, DONDE el blíster además incluye una primera región y una segunda región, incluyendo cada una de las regiones primera y segunda al menos uno de la pluralidad de compartimientos.

5. El envase de medicamento a prueba de niños de la reivindicación 4, DONDE la caja además incluye una primera región y una segunda región, comprendiendo cada una de las regiones primera y segunda al menos una de la pluralidad de aberturas.

6. El envase de medicamento a prueba de niños de la reivindicación 5, DONDE la primera región del blíster está alineada con la primera región de la caja, y la segunda región del blíster está alineada con la segunda región de la caja.

7. El envase de medicamento a prueba de niños de la reivindicación 5, DONDE la primera región de la caja incluye un primer conjunto de instrucciones para administrar el medicamento asegurado en el al menos uno de la pluralidad de compartimientos de la primera región y donde la segunda región de la caja incluye un segundo conjunto de instrucciones para administrar el medicamento asegurado en el al menos uno de la pluralidad de compartimientos de la segunda región.

8. El envase de medicamento a prueba de niños de la reivindicación 1, DONDE la caja está construida de cartulina con una capa de película resistente al desgarro.

9. El envase de medicamento a prueba de niños de la reivindicación 1, DONDE la plancha además incluye una pluralidad de aberturas que se extienden

a través del hueco, configurada cada una de la pluralidad de aberturas para ser complementaria y estar en alineación con uno de la pluralidad de compartimientos .

10. El envase de medicamento a prueba de niños de la reivindicación 1, DONDE la plancha incluye una altura que es mayor que una altura de uno de los compartimientos del blíster.

11. El envase de medicamento a prueba de niños de la reivindicación 1, DONDE la plancha está construida de pulpa de papel y fibra de bambú moldeadas.

12. El envase de medicamento a prueba de niños de la reivindicación 1, DONDE el medicamento asegurado de cada uno de la pluralidad de compartimientos es accesible perforando un sello del blíster.

13. El envase de medicamento a prueba de niños de la reivindicación 1, DONDE la caja está ensamblada y fijada mediante construcción de extremo engomado.

14. El envase de medicamento a prueba de niños de la reivindicación 1, DONDE la caja incluye una tercera pared acoplada de modo abisagrado a la primera pared, superponiéndose la tercera pared a la primera pared para impedir el acceso a la pluralidad de aberturas de la caja .

15. Un método para ensamblar un envase de medicamento a prueba de niños que comprende los pasos de:

alinear un envase blíster que incluye una pluralidad de compartimientos con

una plancha que incluye un hueco y una pluralidad de aberturas, configurada cada una de la pluralidad de aberturas para ser complementaria de uno de la pluralidad de compartimientos ;

anexar el blíster a la plancha;

insertar el blíster y la plancha en una caja , incluyendo la caja una primera pared opuesta a una segunda pared, una pluralidad de aberturas que se extienden a través de la primera pared y están alineadas con una pluralidad de perforaciones de la segunda pared, alineadas cada una de la pluralidad de aberturas y perforaciones para que sean complementarias de uno de la pluralidad de compartimientos ; y

cerrar la caja para encerrar el blíster y la plancha.

16. El método para ensamblar un envase de medicamento a prueba de niños de la reivindicación 15, DONDE insertar el blíster y la plancha en la caja incluye mantener una separación entre la pluralidad de compartimientos y la pluralidad de aberturas de la primera pared.

17. El método para ensamblar un envase de medicamento a prueba de niños de la reivindicación 15, DONDE fijar el blíster y la plancha dentro de la caja incluye superponer y fijar una tercera pared sobre la primera pared.

18. El método para ensamblar un envase de medicamento a prueba de niños de la reivindicación 15, DONDE además comprende imprimir en la caja una serie de instrucciones para administrar el medicamento asegurado dentro de la pluralidad de compartimientos.

19. El método para ensamblar un envase de medicamento a prueba de niños de la reivindicación 15, DONDE además comprende:

proveer al blíster de una primera región y una segunda región , incluyendo cada una de las regiones primera y segunda al menos uno de la pluralidad de compartimientos ;

proveer a la caja de una primera región y una segunda región , incluyendo cada una de las regiones primera y segunda al menos una de la pluralidad de aberturas ;

alinear la primera región del blíster con la primera región de la caja ;

alinear la segunda región del blíster con la segunda región de la caja ;

imprimir en la primera región de la caja una primera instrucción para administrar el medicamento asegurado dentro del al menos uno de la pluralidad de compartimientos de la primera región ; e

imprimir en la segunda región de la caja una segunda instrucción para administrar el medicamento asegurado dentro del al menos uno de la pluralidad de compartimientos de la segunda región .

20. Un método para dispensar a un usuario el medicamento asegurado dentro de un envase a prueba de niños, DONDE comprende los pasos de:

proveer un envase que incluye una caja , una plancha y un envase blíster , fijada la plancha a la caja , y fijado el blíster a la plancha;

aplicar un fuerza al menos a un compartimiento de una pluralidad de compartimientos del blíster , alineado cada uno de la pluralidad de compartimientos con una complementaria de una pluralidad de aberturas de una primera pared de la caja ;

romper un sello del al menos un compartimiento para mover el medicamento contenido en el al menos un compartimiento ;

expulsar el medicamento a través de una abertura del hueco de la plancha, siendo complementaria la abertura del al menos un compartimiento ; y

expulsar el medicamento a través de una perforación de una segunda pared de la caja , siendo complementaria la perforación del al menos un compartimiento .